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ABSTRACT 
 
The hypertensive conditions of pregnancy (including pre-eclampsia (PE)) is 
the leading cause of primary obstetric death in South Africa and affects at 
least five percent of pregnancies in the Western Cape province.  Reduced 
levels of placental protein 13 (PP13) early in pregnancy are associated with a 
higher incidence of PE in later gestation.   PP13 and annexin II have been co-
localised to the brush border membrane of syncytiotrophoblasts, and form a 
complex that is transported to the maternal circulation.  It is speculated that 
genetic variation in the gene encoding annexin II (ANXA2) could underlie the 
reduced PP13 levels. 
 
The aim of this study was to screen the ANXA2 gene, including the proximal 
promoter region, in two South African population groups, (Mixed Ancestry and 
Black) from the Western Cape, to identify whether variants in the ANXA2 gene 
confer susceptibility to PE.  The study cohort comprised of 120 pre-eclamptic 
maternal, 94 pre-eclamptic fetal and 54 healthy control individuals.  Genomic 
DNA of patient and control individuals was extracted for PCR amplification of 
ANXA2 and Multiphor SSCP/HD analysis was performed for mutation 
detection.  The conformational variants identified were subjected to automated 
DNA sequencing and subsequently to RFLP analysis, to confirm the 
genotypes in the remainder of the cohort.  Nine previously identified variants 
(c.-31 T>C, c.292 G>T; p.Val98Leu, c.975 C>T;p.Gly325Gly, c.-12+75 C>A, 
c.-11-43 G>A, c.-11-13 A>T, c.48+67 C>T, c.449-17 G>A, c.683-56 G>A) and 
16 novel variants (c.-442 C>G, c.-191 G>C, c.-189_-188insGCCGG,              
c.-135 C>G, c.-92 A>T, c.222 C>T; p.Ala74Ala, c.600 C>T; p.Asp110Asp, 
c.934 G>A; p.Gly312Ser, c.244-42 G>C, c.244-76 C>G, c.528+38 C>T, 
c.589-5 C>T, c.682+49 C>T, c.961-30 A>G, c.961-24 C>G, c.*1057 A>G) 
were identified upon screening the ANXA2 gene.   Statistical analysis 
identified significant association at five loci: SNP c.-92 A>T located within the 
ANXA2 5‟UTR, exonic SNP c.222 C>T; p.Ala74Ala and three intronic SNPs 
c.244-76 C>G, c.449-17 G>A and c.589-5 C>T.    Three of the five variants 
(c.-92 A>T, c.244-76 C>G, c.589-5 C>T) were significantly associated with PE 
(P<0.05) and could contribute to PE susceptibility in these two SA 
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populations, whereas the other two variants (c.222 C>T; p.Ala74Ala,       
c.449-17 G>A) revealed a possible protective effect, suggesting a reduced 
risk of developing PE.  In silico analysis predicted the disruption and creation 
of several putative transcription factor binding sites by three SNPs in the 
ANXA2 gene, which could subsequently affect ANXA2 functioning.    
 
This study provides evidence for genetic variation in the ANXA2 gene, which 
warrants functional experimental validation in an attempt to investigate the 
function of these SNPs in molecular, cellular and physiological processes 
underlying PE.  Identifying an association between variants in the ANXA2 
gene and PE could contribute to the development of an additional early 
biomarker.  The early identification of PE would promote the South African 
health system by providing the appropriate health care support and monitoring 
of high risk pregnancies, which could ultimately result in improved pregnancy 
outcome.   
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OPSOMMING 
 
Die hipertensiewe siektes van swangerskap (insluitende pre-eklampsie (PE)) 
is die belangrikste direkte oorsaak van moedersterftes in Suid-Afrika en dit 
kom voor by ongeveer 5% van swangerskape in die Wes-Kaap provinsie.  
Verlaagde plasentale proteïen 13 (PP13) vlakke tydens vroeë swangerskap 
word verbind met „n hoër voorkoms van PE in latere swangerskap.  PP13 en 
anneksin II kom albei op die borselgrens membraan van synsitiotrofoblaste 
voor waar hulle „n kompleks vorm wat na die moederlike sirkulasie vervoer 
word.  Daar word gespekuleer dat die onderliggende oorsaak vir laer PP13 
vlakke as gevolg van genetiese variasie in die geen wat anneksin II kodeer 
(ANXA2) kan wees.   
 
Die doel van hierdie studie  was om die ANXA2 geen, insluitende die 
proksimale promoter area, in twee Suid-Afrikaanse populasie groepe, 
(Kleurling en Swart) van die Wes-Kaap, te skandeer met die doel om variante 
in die ANXA2 geen te identifiseer en ‟n moontlike assosiasie met die 
vatbaarheid vir PE te bepaal.  Hierdie studie populasie het bestaan uit 120 
pre-eklamptiese vroue, 94 neonate van pre-eklamptiese ma‟s en 54 gesonde 
kontrole individue.  Genomiese DNS  van die pasiënte en kontrole individue is 
geëkstraeer vir polimerase kettingreaksie amplifikasie van die ANXA2 geen, 
waarna Multiphor enkelstring konformasie polimorfisme heterodupleks analise 
uitgevoer is met die doel om DNS variante te identifiseer.  Die verskillende 
konformasies waargeneem is onderwerp aan semi-geoutomatiseerde DNS 
volgorde bepalingsanalise en gevolglik restriksie fragment lengte polimorfisme 
analise om genotipes in die res van die studiegroep te bevestig. 
 
Vyf-en-twintig variante is geïdentifiseer met die skandering van die ANXA2 
geen, waarvan nege voorheen geïdentifiseer is (c.-31 T>C, c.292 G>T; 
p.Val98Leu, c.975 C>T;p.Gly325Gly, c.-12+75 C>A, c.-11-43 G>A,               
c.-11-13 A>T, c.48+67 C>T, c.449-17 G>A, c.683-56 G>A) en 16 nuwe 
variante is (c.-442 C>G, c.-191 G>C, c.-189_-188insGCCGG, c.-135 C>G,     
c.-92 A>T, c.222 C>T; p.Ala74Ala, c.600 C>T; p.Asp110Asp, c.934 G>A; 
p.Gly312Ser, c.244-42 G>C, c.244-76 C>G, c.528+38 C>T, c.589-5 C>T, 
vi 
 
c.682+49 C>T, c.961-30 A>G, c.961-24 C>G, c.*1057 A>G).  Statistiese 
analise het „n statisties beduidende assosiasie met vyf SNPs geïdentifiseer: 
SNP c.-92 A>T geleë in die ANXA2 5‟UTR, die koderende SNP c.222 C>T; 
p.Ala74Ala en drie SNPs c.244-76 C>G, c.449-17 G>A and c.589-5 C>T 
geleë in die nie-koderende areas.   Drie van hierdie vyf SNPs (c.-92 A>T,           
c.244-76 C>G, c.589-5 C>T) het statisties beduidende assosiasie met PE 
(P<0.05) getoon en kan bedra tot die vatbaarheid vir PE in hierdie twee Suid-
Afrikaanse populasies, terwyl die ander twee SNPs (c.222 C>T; p.Ala74Ala, 
c.449-17 G>A) „n moontlike beskermende effek gedui het, wat „n verlaagde 
risiko vir die ontwikkeling van PE voorstel. In silico analise het voorspel dat 
verskeie voorgestelde transkripsiefaktor bindingsetels onderbreek of geskep 
sal word in die teenwoordigheid van drie SNPs in die ANXA2 geen, wat 
gevolglik die funksionering van ANXA2 kan affekteer.   
 
Hierdie studie verskaf bewyse vir genetiese variasie in die ANXA2 geen, wat 
verdere funksionele eksperimentele ondersoeke vereis om die funksie van 
hierdie SNPs in molekulêre, sellulêre en fisiologiese prosesse onderliggend 
aan PE te bepaal.  Die identifisering van ‟n assosiasie tussen variante in die 
ANXA2 geen en PE kan bydra tot die ontwikkeling van ‟n addisionele vroeë 
genetiese merker.  Die vroeë identifisering van PE kan die Suid-Afrikaanse 
gesondheidsisteem geweldig baat deurdat die geskikte gesondheidsorg en 
ondersteuning asook deurgaanse monitering van hoë risiko swangerskappe 
verskaf sal kan word.  Dit kan uiteindelik lei tot ‟n verbeterde uitkoms vir 
swangerskappe in Suid-Afrika.   
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1 LITERATURE REVIEW 
 
1.1 Pregnancy 
 
1.1.1 Normal Pregnancy  
 
The gestational period “involves an intricate interplay of intracellular and 
extracellular factors including hormones, adhesion molecules, growth factors 
and immunomolecules” to allow for a normal and healthy pregnancy to 
proceed (Shankar et al., 2005).   
 
i) Fertilisation, Implantation and Placentation 
 
Following conception, the fertilised ovum undergoes a series of cell divisions, 
known as cleavage.  Three days following fertilisation, further cell divisions 
result in the formation of a cluster of cells and at this point, the embryo is 
known as the “morula”.   From day five after conception, the morula reaches 
the uterus and the blastocyst cavity starts to develop.  During the following 
two days, a layer of trophoblasts cells forms an outer layer of cells around the 
blastocyst, and on the inside of the trophoblast layer of cells, a cluster of cells, 
known as an inner cell mass (embryoblast) develops.  The embryoblast 
develops into the embryo, while trophoblast cells give rise to extra-embryonic 
structures such as the placenta and membranes.   
 
The blastocyst sheds the zona pellucida, a glycoprotein membrane enclosing 
the plasma membrane of the developing oocyte and develops until it is fully 
exposed to the uterine cavity, after which it adheres and implants into the 
uterine wall (Martini and Bartholomew, 2003).  The attachment of the 
blastocyst to the endometrial epithelium initiates the differentiation of the 
trophoblast cells into an inner cytotrophoblast and an outer 
syncytiotrophoblast cell layer.  During the second week of gestation, the 
blastocyst cavity and implanting embryo have developed into the primary yolk 
sac and blastocyst, respectively.   
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Ten days after conception, implantation of the fully developed blastocyst into 
the uterine lining has taken place (Benirschke et al., 1991).  During this time 
the trophoblast cells divide to form a thicker outer layer.  The cell membrane 
in contact with the endometrium disappears to form an outer layer that 
consists of multi-nucleated cytoplasm, known as the syncytiotrophoblast layer.  
As the blastocyst becomes completely imbedded into the uterine wall, further 
development of the embryo takes place in the endometrium.     
 
The syncytiotrophoblast cells continue to develop and function as the provider 
and distributor of nutrients to the inner cell mass and play an essential role in 
the development of the early embryo.  Trophoblasts continue to grow and 
develop, to facilitate a change (“re-modelling”) in maternal spiral arteries into 
low resistance vessels that would cause increased maternal blood to flow 
through lacunae to ensure sufficient perfusion of the embryo (Figure 1.1a and 
Figure 1.2) (Caniggia et al., 2000; Norris, 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1a Trophoblast invasion in a normal pregnancy (Serrano, 2006). 
 
 
Normal trophoblast invasion 
Uncomplicated pregnancy 
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1.1.2 Abnormal Pregnancy 
 
i) Impaired Invasion and Perfusion 
 
In previous studies defective endovascular trophoblast invasion and “shallow” 
interstitial trophoblast invasion (Redman and Sargent, 2005) have been 
associated with pregnancy-related disorders such as miscarriage, preterm 
labour, intra-uterine growth restriction (IUGR) and pre-eclampsia (PE) (Kim et 
al., 2003; Ozturk et al., 2004).  Insufficient transformation of maternal spiral 
arteries leads to a reduction in intervillous blood flow and could lead to a 
subsequent reduction in the concentration of oxygen and nutrients supplied to 
the fetus (Caniggia et al., 2000).                   
                                                         
          
 
 
 
 
 
 
 
 
 
Figure 1.1b Inadequate trophoblast invasion in pre-eclamptic pregnancies 
(Serrano, 2006). 
Inadequate trophoblast invasion and defective 
remodeling of spiral arteries 
Placental ischaemia and inflammation 
ENDOTHELIAL DYSFUNCTION 
PRE-ECLAMPSIA 
Systemic 
inflammation 
Apoptosis Free radicals 
Release of toxic 
substances 
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A certain systemic concentration of the cytokines VEGF (vascular endothelial 
growth factor) and PIGF (placental growth factor), produced by natural-killer 
cells, are maintained during a normal pregnancy.  These cytokines are 
angiogenic factors which play an imperative role in maintaining the maternal 
endothelial state and uteroplacental circulation during pregnancy, by binding 
to the receptors Flt-1 (Fms related tyrosine kinase 1) and KDR (kinase insert 
domain receptor) (Maynard et al., 2003).  Normal pregnancies have lower 
sFlt-1 (secreted splice variant of FLT-1) concentrations compared to 
increased sFlt-1 levels in the placenta and serum of women with PE (Maynard 
et al., 2003; Buhimschi et al., 2005).  Elevated systemic levels of sFlt-1 are 
associated with PE, since the levels normalise with the delivery of the 
placenta.  During PE, the systemic concentration of free VEGF and PIGF are 
decreased, most likely because increased levels of the soluble form of 
placenta-derived sFlt-1, an antagonist of VEGF, binds and inhibits VEGF and 
PIGF (Figure 1.2) (Burri et al., 2004; Sibai et al., 2005).  VEGF factors either 
bind to trans-membrane receptors or sFlt-1, which in both cases, result in the 
inhibition of VEGF activity (Clark et al., 1998; Maynard et al., 2003). This 
subsequently inhibits trophoblast invasion and maternal endothelial and 
vascular transformation, which result in a similar phenotype that have 
previously been associated with PE (Figure 1.1b) (Caniggia et al., 2000; 
Norris, 2005).    
5 
 
 
Figure 1.2 Remodeling of the spiral arteries in normal pregnancy versus pre-
eclamptic pregnancy (Caniggia et al., 2000). 
 
1.2 PE as a Complex Genetic Disease 
 
Impaired placental implantation and development are associated with the 
pathophysiology of PE (Roberts and Cooper, 2001), even though the placenta 
may have normal weight and surface area at birth in a PE patient (Teasedale, 
1985).  PE occurs only during pregnancy, suggesting that the placenta or 
fetus may contribute to the disease process (Cross, 2003). Although the 
etiology, as well as the influence of genetic factors on PE are still unknown, 
several associations between genetic variants in genes such as the 
Glu298Asp polymorphism in the endothelial nitric oxide synthase (eNOS) 
gene and the Leiden mutation in the Factor V gene and PE have been 
identified (Dizon-Townson et al., 1996; Serrano et al., 2004; Hillermann et al., 
2005).  It was found that these variants could possibly affect the function of 
the genes and consequently be implicated in the pathophysiology of PE.  
Mutations in the methylenetetrahydrofolate reductase (MTHFR) gene have 
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been associated with PE in several populations (Grandone et al., 1997; 
Sohda et al., 1997) but these associations could not be confirmed by 
subsequent studies (Chikosi et al., 1999; Kaiser et al., 2000; Rajkovic et al., 
2000).  Since the SNP T235 in the coding region of the angiotensinogen 
(AGT) gene was first identified and found to be associated with PE (Ward et 
al., 1993), it was shown that the T235 SNP was indeed associated with the 
abnormal development of spiral arteries, a physiological abnormality known to 
be associated with PE (Morgan et al., 1999).  These above-mentioned genes 
and variants implicated in and associated with the pathophysiology of PE are 
only a glimpse on the complexity of this devastating genetic disease.    
 
1.3 Clinical Symptoms of PE 
 
According to the ISSHP (International Society for the Study of Hypertension in 
Pregnancy) PE can be identified by hypertension associated with blood 
pressure levels of 140/90 mmHg or more, measured on two occasions, at 
least 4 hours apart (Davey and MacGillivray, 1988).  These elevated blood 
pressure levels along with significant proteinuria is diagnostic of PE after 20 
weeks of gestation in a previously normotensive, non-proteinuric woman. 
Headaches, blurred vision, hyperreflexia, epigastric pain and edema are all 
clinical symptoms or signs of PE.  PE could lead to eclampsia and possibly 
death, if not managed correctly (Cross, 2003).  
 
1.4 Complications – Fetal and Maternal Implications 
 
Universally PE affects five to six percent of pregnancies.  In the USA, PE 
causes approximately 18% of maternal deaths (Chafetz et al., 2007), in 
contrast to 42% of maternal deaths caused by PE in developing countries 
such as India and Columbia (Villar et al., 2004).  In the Western Cape 
province of South Africa (SA), at least five percent of pregnancies are affected 
by PE (Hall et al., 2006; Kenneth et al., 2008) although nationally the figure 
may be much higher due to pregnancies being managed without appropriate 
health care support. 
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There are currently several programs and approaches in place to successfully 
manage PE in hospitals, but despite these attempts, SA is still losing many 
mothers to this devastating disease.  The NCCEMD (National Committee on 
Confidential Enquiries into Maternal Deaths in SA) report identified the 
primary reasons for these deaths in South Africa.  The most recent Saving 
Mothers Report (2005 – 2007), released by the Department of Health, listed 
Non-Pregnancy Related Infections, which include infections such as 
pneumonia, HIV-AIDS and Tuberculosis as the primary cause of indirect 
maternal deaths between 1999 and 2007 (Figure 1.3) (Department of Health, 
www.doh.gov.za).   Hypertension, accountable for 15.7% of maternal deaths 
during the period from 2005 to 2007 includes all cases with Chronic 
Hypertension, Pregnancy Induced Hypertension (PIH) and PE. 
 
Primary obstetric causes of death in SA (1999-2007)
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Figure 1.3  Trend of primary obstetric causes of maternal deaths in SA (1999 
– 2007) (Saving Mothers Report, Department of Health, www.doh.gov.za) 
(Abbreviations: AA, Anaesthetic Related; AB, Abortion; AC, Acute Collapse; 
Emb, Embolism;  APH, Antepartum Haemorrhage; Ep, Ectopic Pregnancy; 
HT, Hypertension; NPRI, Non-Pregnancy Related Infections; MD, Pre-existing 
Medical Disease; PPH, Postpartum Haemorrhage; PRS, Pregnancy Related 
Sepsis; Unk , Unknown). 
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1.5 Risk Factors for Developing PE  
 
 i) Maternal, Paternal and Fetal Related Risk Factors 
 
Maternal risk factors for developing PE include aspects such as a family 
history of PE, previous pregnancy with PE, and maternal age above 40 years 
(Figure 1.4) (Chappell and Morgan, 2006; Serrano, 2006).  PE is known as a 
“disease of first pregnancy” and a previous normal pregnancy is thus 
suggested as a protective factor against the development of PE.  This, 
however, is usually only true in the case of long-term sperm exposure to the 
same partner and if the partner has not previously fathered a PE pregnancy 
(Tubbergen et al., 1999; Verwoerd et al., 2002; Skjearven et al., 2005).  
Impaired trophoblast invasion or multiple pregnancies (twins, triplets) could 
lead to the insufficient transformation of maternal spiral arteries, which would 
subsequently affect placental perfusion, increasing the risk to develop PE 
(Redman and Sargent, 2005).   
 
i) Risk caused by the Presence of Underlying Disease 
 
Risk factors that may play a role in predisposing women to PE can include 
underlying complex disorders such as obesity, diabetes, chronic hypertension, 
renal and autoimmune diseases (Figure 1.4) (Chappel and Morgan, 2006; 
Serrano, 2006).  Obesity and diabetes are complex disorders that are 
increasingly becoming more prevalent across the world.  Since these       
above-mentioned diseases have a strong link with each other and are strongly 
associated with insulin resistance, a study by Dekker and Sibai (2001) 
suggested that a decrease in obesity could subsequently result in a decrease 
in the frequency of PE. 
 
Hypertension during pregnancy has previously been associated with the 
future development of cardiovascular disease (CVD) (Mann et al., 1976). A 
study by Jonsdottir et al. (1995) found that PE was associated with an 
increased risk to CVD, since the underlying disease mechanism of PE shares 
many risk factors with CVD and not hypertension as such.  It is therefore 
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suggested that the factors involved in the disease mechanisms of PE and 
CVD could be shared (Rodie et al., 2004).  Although the risk of young women 
to develop CVD is low, screening for common genotypic and phenotypic 
factors in these two life threatening diseases could allow for early intervention 
and therapeutic appraoches for prevention and managing of CVD.   
 
ii) External Related Risk Factors 
 
Cigarette smoking has previously been associated with a reduced risk for the 
development or incidence of PE (Sibai et al., 1995; Conde-Agudelo and 
Belizan, 2000). Interestingly, in the study by Sibai et al. (1995) women who 
stopped smoking just before pregnancy had a lower risk of developing PE 
than women who kept smoking throughout pregnancy. Compared to the 
harmful effect of smoking on fetal development, birth weight, placental 
abruption and general health, this advantage seems minor.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4  A schematic diagram indicating maternal and fetal/placental risk 
factors for PE (Chappell and Morgan, 2006).  
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iii) Genetic Risk Factors 
 
Women at-risk of developing PE need to be identified as early as possible, as 
the primary objective is to facilitate preventative approaches and programmes 
to prevent the development of PE.  A genetic biomarker to assist in the early 
identification of women at risk for PE would allow for closer observation and 
immediate medical care (Carty et al., 2008).   
 
1.6 Treatment of - and Prophylaxis to At-Risk Individuals 
 
 i) Vitamin C and Vitamin E 
 
Oxidative stress and endothelial damage are implicated in abnormal 
pregnancies such as PE.  The intake of certain antioxidants, such as vitamin 
C (ascorbic acid) and vitamin E (alpha-tocopheral) are known to inhibit the 
performance of reactive oxygen species and lipid peroxidation, theoretically 
resulting in a reduced risk of PE (Chappell et al., 1999).   More recently, a 
study by Poston et al. (2006) contradicted this hypothesis, by not finding an 
association between the intake of vitamin C and vitamin E and a reduction in 
risk of PE.  
  
 ii) Low-Dose Aspirin 
 
Over the years, several studies indicated that low-dose aspirin (60 – 100 mg a 
day) decreased the risk of PE (Wallenburg et al., 1986; Sibai et al., 1993).  
Low dose aspirin may favour a prostacyclin preference in the thromboxane A2 
– prostacyclin correlation, as thromboxane is responsible for physiological 
abnormalities such as vasospasms and coagulant problems associated with 
PE (Sibai et al., 1993). 
 
ii) Magnesium Sulphate 
 
The chemical compound magnesium sulphate has been used as a 
prophylaxis in women with acute PE in attempt to decrease their risk of 
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developing eclampsia (convulsions) (Hall et al., 2000).  Eclampsia is a serious 
complication of PE with generalized convulsions that can lead to intracranial 
bleeding if not controlled.  A more recent study by Sibai (2005) confirmed that 
magnesium sulphate has been associated with a reduced risk for developing 
eclampsia when administered in the acute phase.   
 
1.7 Biomarkers for PE 
 
Biomarkers have previously been defined as “biological characteristics that 
can be objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes or pharmacological responses to 
a therapeutic intervention” (Naylor, 2003). Over the years PE has been 
studied extensively with the primary aim of identifying possible risk factors and 
biomarkers to timeously identify women at-risk of this devastating condition.  
Recognising clinical, genetic, proteomic and metabolic risk factors in an 
attempt to successfully identify women at risk of PE is important for the 
survival and wellbeing of the unborn fetus and the mother.   
 
1.7.1 PP13 as Maternal Biomarker 
 
Pregnancy-related proteins, such as PP13 are only expressed during 
pregnancy (Than et al., 2004).   PP13 levels measured in maternal serum in 
pre-eclamptic pregnancies were found to be lower in the first trimester and 
higher in the second and third trimesters, when compared to PP13 levels in 
normal pregnancies (Figure 1.5) (Burger et al., 2004).    Altered levels of PP13 
in PE patients could therefore be an indicator or cause of impaired placental 
function (Burger et al., 2004).     
 
Serum PP13 was isolated in 1983 by Bohn and his colleagues (Bohn et al., 
1983) and has since been fully characterised by DTL (Diagnostic 
Technologies Ltd.).  PP13 is a member of the galectin superfamily which is 
known for roles in cellular differentiation and proliferation (Perillo et al., 1998).  
PP13 is encoded by the LGALS13 gene (NM_ 013268) which is located on 
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the long arm of chromosome 19 (19q13. 1) and consists of two equal 16 kDa 
subunits that are held together by disulphide bonds.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 PP13 levels measured during normal and pre-eclamptic 
pregnancies.  Abbreviations: GW, gestational week, PET, pre-ecalmpsia.  
(Image: Dr M Sammar, workshop presentation at the IFPA conference, 2008). 
 
Placental Protein 13 (PP13), as a disease biomarker, could play a pivotal role 
in early detection of various pregnancy complications due to placental 
insufficiency (Chafetz et al., 2007; Spencer et al., 2007).  PP13 levels can be 
measured relatively easily, in comparison to Doppler Ultrasonography of the 
uterine arteries, which is restricted to specialised centres. PP13 levels are 
measured using ELISA which can be performed during the first trimester of 
pregnancy (Burger et al., 2003).   
 
Doppler Ultrasonography is routinely used to determine the velocity of uterine-
artery blood flow from the 20th to 24th week of pregnancy when results may be 
provided too late for possible intervention (Nicolaides et al., 2006).  In 
addition, the sensitivity for predicting PE is only 20%-60% and the false 
positive predictive rate 6% to 40% using this screening technique alone during 
the first trimester (Yu et al., 2003; Nicolaides et al., 2006).  PP13 
measurement in maternal body fluid, such as maternal serum, would therefore 
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be a more accurate and reliable screening tool when used in combination with 
Doppler Ultrasound since a sensitivity of 90% has been reported (Nicolaides 
et al., 2006). PP13 as biomarker would allow for early intervention and 
treatment of PE and monitoring of high-risk pregnancies (Burger et al., 2004).    
 
1.7.2 Reasons for Altered PP13 Levels 
 
Reasons for the altered PP13 levels observed in pre-eclamptic pregnancies 
are currently unknown.  DNA mutations in the LGALS13 gene may have an 
effect at the level of transcription, influencing the mRNA transcript.  Errors 
during mRNA processing or transport, could affect the stability of RNA, 
subsequently affecting translation.  Alterations at post-translational 
modification eg, glycosylation and protein folding, could also lead to the 
production of a defective protein (Lorkowski and Cullen, 2003; Burger et al., 
2004).    Furtermore, disabled transport of perfectly formed PP13 across the 
fetal-maternal interface into maternal circulation, could also contribute to 
decreased/altered PP13 levels. However, to date little is known about the 
transport of PP13 to the extracellular syncytiotrophoblast apical membrane 
(Than et al., 2004). 
 
1.8 Galectin Family 
 
Galectins are soluble cytoplasmic proteins that contain either one or two 
conserved carbohydrate recognition domains (CRDs) that consist of 135 
amino acids (Lobsanov et al., 1997; Than et al., 2004). The mammalian 
galectin family consists of 13 galectins (galectins 1 to 10 and 12 to 14) and 5 
proteins similar to galectins namely GRIFIN, HSPC159, PP13, PPL13 AND 
OvGal11.  Members of the galectin family can be subdivided into three 
classes; prototype, chimera and tandem repeat, according to their individual 
structures (Figure 6) (Barondes et al., 1994a). Prototypes (galectins 1, 2, 5, 7, 
8, 10, 11, 13, 14) represent galectins that contain either one (monomers) or 
two (dimers) CRDs in a single peptide.  Chimeras (galectin 3) are rare 
galectins, which contain a large CRD, consisting of multiple repeats on a 
domain that exert numerous functions (Bidon et al., 2001).  A small peptide 
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separates two CRDs on a single protein chain to form a tandem repeat 
(galectins 4, 6, 8, 9, 12).   
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Galectin sub-classes (Adapted from: Hughes, 1999). 
 
1.8.1 PP13 as a Member of the Galectin Family 
 
In a study by Than et al. (1999), a CRD identified in PP13 was shown to be 
identical to the structure of other members of the galectin family.  PP13 has 
demonstrated conservation to other members of the galectin family on various 
levels, such as DNA sequence, gene structure and general functioning 
(Barondes et al., 1994a). A three dimensional (3-D) model of PP13, 
constructed to substantiate homology to the galectin family, confirmed PP13 
as new member of the galectin family, and was named galectin-13 (Figure 
1.7) (Visegrady et al., 2001).   
 
Galectins show an affinity for β-galactosides (Barondes et al., 1994b), but 
have various additional functions, depending on their location and structure.  
Most galectins have previously been implicated in cell - cell interactions, cell 
adhesion and cell signaling (Hughes, 2001).   In addition, members of the 
galectin family are well characterised in the roles they play in inflammation 
and immune responses.  Therefore, PP13/galectin 13 was assigned similar 
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functions and was thought to play an imperative role in the exchange of blood 
between the mother and fetus (Than et al., 2004).   
            
Figure 1.7 Proposed PP13/galectin-13 complex structure Than et al. 
(2004).  RASMOL identified cysteine residues on beta-sheets F1 (Cys136, 
Cys138), F2 (Cys19) and F3 (Cys92), along with a highly conserved 
tryptophan (Trp72) residue on beta-sheet S6a.  Beta-sheet F4 and C- and N-
termini are indicated (Than et al., 2004).   
 
Individual galectins are expressed in various healthy and disease-affected 
tissues and are differentially regulated.  A study by Than et al. (2004) 
confirmed that PP13/galectin-13 was not only strongly expressed in the 
placenta, but also at markedly lower levels in healthy spleen, kidney and 
bladder tissues along with liver adenocarcinoma, neurogen tumour and 
malignant melanoma (Figure 1.8) (Visegrady et al., 2001).  
Figure 1.8 Expression profile of the LGALS13 gene in various human 
tissues. (Retrieved from: GNF SymAtlas, http://biogps.gnf.org). 
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1.8.2 Secretion of Galectins 
 
When galectins are bound to cell surface receptors they exert essential 
extracellular functions (Hughes, 1999).  Their secretion is regulated by several 
factors, including cytokines and membrane fusion events, as they move from 
cells either in free form or contained within vesicles.  Cytosolic proteins, 
clustered below the plasma membrane in the cytoplasm, are excreted as 
extracellular vesicles that protrude from the plasma membrane as “blebs” 
(Figure 1.9) (Hughes, 1999).   Some galectins (galectins 1and 3) are secreted 
via ectocytosis from fibroblasts within microvesicles, in conjunction with high 
amounts of actin and annexin II (Than et al., 2004).   
 
Figure 1.9 Secretion of galectins eg, galectin 3 (Hughes, 1999). 
 
1.8.3 Proteins Associated with PP13 
 
In a study conducted by Than et al. (2004), proteins PP13-B (purified from 
human placenta) and PP13-R (recombinant PP13 protein) were immobilised 
to determine which proteins were bound to PP13.  MALDI-TOF MS peptide 
mapping and sequencing revealed that PP13-B and PP13-R were specifically 
bound to annexin II and beta/gamma actin in placental and fetal hepatic cells.  
This was confirmed by co-localisation of PP13/galectin-13 and annexin II (as 
A2-S100A10 heterotetramer) on the outer cellular membrane of 
syncytiotrophoblasts. Staining of placental tissue with anti-annexin II 
antibodies revealed the presence of annexin II in syncytiotrophoblasts and the 
brush border membrane (Figure 1.10) (Than et al., 2004). 
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Figure 1.10 Localisation of PP13 with annexin II on the brush border  
membrane (Than et al., 2004).  Green is an indication of annexin II staining in 
the syncytiotrophoblasts.  Arrows indicate more intense staining observed in 
the brush border membrane.  
 
1.9 Annexin Gene Family 
 
In Greek, annexin refers to the word annex that means to “bring or hold 
together” (Gerke and Moss, 2002).   The annexin multigene family is classified 
according to a conserved region, consisting of a 70 amino acid repeat, of 
which a sequence of 17 amino acids has been found to be particularly 
conserved.  This area occurs four times within the various annexin genes 
(Spano et al., 1990).  The conserved core of the annexin sequence consists 
of 310 residues that contain type-2 motifs for the binding of Ca2+ ions (Aukrust 
et al., 2006).  While each annexin has particular properties because of its 
individual protease-sensitive N-terminal tails of variable length (Spano et al., 
1990), collectively the conserved domains, and the distinctive properties of 
each annexin most likely play a vital role in their general functioning (Moss 
and Morgan, 2004).   
 
The annexin family thus consists of globular proteins that are structurally 
related.  In the presence of Ca2+, annexins associate with amniotic 
phospholipids (aPL) (Aukrust et al., 2006).  Annexins can be categorized into 
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three groups according to their structure; ANXA7, ANXA11 and ANXA13 are 
the earliest vertebrate annexins, ANXA4, ANXA5 and ANXA8 form the second 
group and ANXA1, ANXA2 and ANXA3 are part of the third group (Gerke and 
Moss, 2002).  Annexins ANXA9 and ANXA10 are seen as distant-related 
members of the annexin family and ANXA6 is difficult to assign because of its 
similarity to the annexins in both the second and third groups.   
 
1.9.1 Annexin V Gene 
 
Annexins interact with each other in such a way, that one annexin regulates 
the function of another. A direct interaction between annexin II and annexin V 
was observed in a study by Brooks et al. (2002), suggesting that annexin II 
may possibly bind directly to annexin V. 
 
Genetic defects often associated with recurrent pregnancy loss (RPL, another 
association with poor placentation) are the Factor V Leiden mutation and the 
Factor II 20210 G/A mutation, along with the presence of maternal 
antiphospholipid antibodies (aPL) (Empson et al., 2002).  Reduced levels of 
the placental anticoagulant protein, annexin V, expressed on the placental 
trophoblasts, have not only been documented in the presence of aPL (Rand 
et al., 1994) but have been implicated in the pathophysiology of PE (Shu et 
al., 2000). It was found that DNA sequence variants in the ANXA5 gene 
possibly influenced annexin V expression (Bogdanova et al., 2007).  ANXA5 is 
localised to chromosome 4q27, has a genomic span of approximately 9 kb 
and consists of 12 exons (Rand and Wu, 1999).  
 
In the study by Bogdanova et al. (2007) the over-expression of a haplotype    
(-19 G/A, 1 A/C, 27 T/C, 76 G/A), named M2, located within the ANXA5 
promoter, was associated with RPL.  The patients in the study cohort were 
pre-screened for thrombophilic genetic factors to ensure the reason for the 
reduced ANXA5 levels most likely caused by the seqeunce variants identified 
in the promoter region (Bogdanova et al., 2007).    Functional reporter gene 
assays in heterozygous individuals revealed a significant decrease of 37% - 
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42% in ANXA5 expression, compared to normal expression levels in wild-type 
individuals.  Both ANXA2 and ANXA5 have been implicated in pregnancy-
related disorders such as PE, which would suggest that studying the promoter 
area of the ANXA2 gene parallel to the study by Bogdavona et al. (2007) 
could potentially reveal a similar haplotype in the ANXA2 promoter area.  
 
1.10 The Annexin II Gene 
 
Human annexin II was first isolated from the placenta as a phospholipase A2 
inhibitor, known as lipocortin II (Huang et al., 1986).  Annexin II is therefore 
part of the human lipocortin-2-encoding multigene family.   
 
The Annexin II (ANXA2) gene (NM_001002858) is located on the long arm of 
chromosome 15 (15q21) (Spano et al., 1990), while its three intronless 
pseudogenes ANX2P1, ANX2P2 and ANX2P3 (NR_001562; NR_003573.1; 
NR_001446) are located on chromosomes 4q21-q31, 9p13 and 10q21-q22, 
respectively (Huebner et al., 1988; Spano et al., 1990).   
 
The ANXA2 gene is represented by four alternative mRNA transcripts.  These 
transcripts differ in length (ie, the length of the N-terminus is shorter in 
transcripts 2, 3 and 4 as opposed to transcript 1) and structure (ie, the 
position of the translational start site is downstream in isoforms 2, 3 and 4 as 
opposed to that of transcript 1), but three of the four transcripts encode the 
same isoform 2.  Figure 1.11 represents a comparison of the four different 
annexin II transcripts as retrieved from the Entrez Gene database 
(http://www.ncbi.nlm.nih.gov/gene/, 1 September 2009).  
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Figure 1.11 Comparison between the four transcript variants for the ANXA2     
gene. (Retrieved from: Entrez Gene database, http://www.ncbi.nlm.nih.gov/gene/) 
 
The gene structure for ANXA2 has been documented.  ANXA2 consists of 13 
exons and has a genomic span of 40 kb.  In the 5‟ untranslated region of the 
ANXA2 gene, a canonical TATA box, three binding sites for transcription 
factor Sp1 and a consensus sequence for transcription factor AP-1 have been 
reported (Spano et al., 1990).   
 
1.10.1 Association of S100A10 with Annexin II (A2-S100A10 
 Heterotetramer) 
 
Interactions between S100A10 subunits (also known as p11 subunits) which 
bind to the N-terminal region of annexin II (also known as p36 molecule), 
result in the formation of the annexin A2-S100A10 heterotetramer (AIIt) 
(Kaczan-Burgouis et al., 1996; Gerke and Moss, 1997).  The S100A10 S100 
Ca-binding protein A10, encoded by the S100A10 gene, is located in the 
cytoplasm and nucleus of various cells.  The S100 protein family consists of at 
least 13 members, all localised to chromosome 1q21, of which S100A10 is 
thought to play a role in exocytosis and endocytosis.  Amino acid 
replacements in the Ca2+ binding loops result in inactive Ca2+ binding sites on 
S100A10 causing this protein to be in a permanently active state (Rety et al., 
1999).  The A2-S100A10 heterotetramer consists of two 36 kDa annexin II 
(p36) molecules linked to two 11 kDa S100A10 (p11) protein subunits                   
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(Figure 1.12b) (Gerke and Moss, 2002).  Annexin II is therefore essentially 
present in the cytosol as a monomer (p36) while the A2-S100A10 
heterotetramer complex (AIIt) is able to associate with the plasma membrane 
(Thiel et al., 1993; Waisman, 1995).  
 
A low-resolution crystal structure confirmed that the two annexin II molecules 
(red) are structured on either side of the two S100A10 subunits (dark and light 
blue) in the centre (Figure 1.12b) (MacLeod et al., 2003).  According to Lewit-
Bentley et al. (2000), the high resolution crystal structure of the core domain 
of annexin II illustrated that the one S100 (p11) subunit binds to the  N-
terminal region (yellow) of annexin II (Figure 1.12 a, b).     
 
 
a)        b)  
 
Figure 1.12 (a) The structure of the complex of p11 with the N terminal 
region of annexin II (Kraulis et al., 1991).  (b) The heterotetrameric complex 
(AIIt) of S100A10 (p11) with annexin II (p36) (Kraulis et al., 1991).      
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1.10.2 Expression of the Annexin Family 
 
Annexin II levels vary mainly when present in the form of the AS-S100A10 
heterotetramer (Kaczan-Bourgois, 1996).  Annexins are expressed in various 
tissues at different stages, with annexins I, II, V and VI being expressed in 
syncytiotrophoblast epithelium, and annexins II and V localised in intestinal 
epithelia (Figure 1.13) (Glenney et al., 1987).  In a study by Kaczan-Bourgois 
(1996), annexin II (p36) and S100A10 (p11) levels in the synciotrophoblast 
apical membrane were found to gradually increase during pregnancy.   Since 
annexin II has been associated with endocytosis and exocytosis, it could 
possibly be implicated in transport systems in the brush-border membrane 
vesicles of the placental syncytiotrophoblast (Kaczan-Bourgois et al., 1996).   
 
 
Figure 1.13 Expression profile of the ANXA2 gene in various human tissues.   
(Retrieved from: GNF SymAtlas, http://biogps.gnf.org). 
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1.10.3 Function of Annexin II 
 
Annexin II has been assigned many functions of which “membrane trafficking” 
is the result of its involvement in in vitro interactions and various effects on 
membranes (Brooks et al., 2002).  Annexin II is known to play an essential 
role in a number of biological processes such as the regulation of cell growth 
and differentiation in the placenta throughout pregnancy, and signal 
transduction pathways (Creutz, 1992; Baldwin et al., 2005;                             
Aukrust et al., 2006).  
 
Another function of annexin II, receiving growing support in the literature, is its 
“anti-thrombic role at the endothelial cell surface” (Gerke and Moss, 2002).  It 
is hypothesized that the reduced levels of functional annexin II on the surface 
of vascular endothelial cells may lead to a predisposition to cardiovascular 
disease.  Additionally, numerous studies have suggested that annexin II plays 
an important role in fibrin homeostasis.  A study by Fleury et al. (1993) 
indicated that human annexin II binds t-PA or plasminogen at the carboxyl-
terminal lysines of S100A10, stimulating t-PA-dependent plasmin production.  
A2-S100A10 therefore functions as a plasminogen regulatory protein, 
increasing general fibrinolytic activity.  A defective annexin II molecule would 
inhibit catalytic plasmin activity (Cesarman-Maus and Hajjar, 2005), 
preventing plasmin generation, which would subsequently prevent fibrin 
degradation, and ultimately would prevent a fibrin hemostatic clot from being 
dissolved.  
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1.11 Study Hypothesis  
 
Based on the evidence provided, we hypothesized that DNA sequence 
variants in the ANXA2 gene may affect PP13/annexin II binding and in this 
indirect manner, impact on PP13 transport and facilitate reduced PP13 protein 
levels observed in pre-eclamptic pregnancies.  Currently, little is known about 
genetic variation in the ANXA2 gene.  This case-control study is therefore a 
platform to clarify our hypothesis, but also to serve as a foundation for future 
studies. Results acquired from this research will contribute towards 
understanding the association between specific genetic variants in the ANXA2 
gene and PE, in addition to contributing to the understanding of the 
pathogenesis of this complex disease.  
 
1.12 Aim of this Study 
 
The aim of this study was to characterise the sequence variation in the 
ANXA2 gene in pre-eclamptic pregnancies.  
 
This would be achieved by the following objectives: 
1. searching for sequence variation in the ANXA2 gene and comparing 
the frequencies of the identified variants in healthy and pre-eclamptic 
pregnancies,  
2. performing detailed statistical analyses to determine a possible 
association between the ANXA2 gene variants and PE, 
3. performing in silico analysis to determine the predicted effects of the 
identified variants on annexin II function. 
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2 MATERIALS AND METHODS  
 
MATERIALS 
 
2.1 Study Cohort 
 
Institutional approval was granted for this study by the Ethical Review 
Committee of the Faculty of Health Science of Stellenbosch University 
(N05/07/122), and written informed consent was obtained from all the 
participants (Appendix A).  A complete clinical data set for each patient is 
available at Tygerberg Hospital.   
 
Maternal and fetal patient and control cohorts were recruited from Tygerberg 
Hospital in the Western Cape, South Africa.  The underlying etiology of PE is 
unkown and maternal and fetal samples were included in the patient study 
cohort since genetic variation in the ANXA2 gene in either maternal or fetal 
samples could contribute to our understanding of the pathology of PE.  The 
maternal patient cohort (n=120) consisted of 71 Mixed Ancestry and 49 South 
African Black women who have clinically been diagnosed with early onset PE.  
Early onset severe PE was diagnosed when the onset of disease was before 
34 gestational weeks. Pre-eclampsia was defined by two diastolic blood 
pressure measurements of 90 mmHg or more, at least 4 hours apart, coupled 
with significant proteinuria of 0.3 g/24 h or more or persistent 2+ on dipsticks.  
The smaller sample size for the fetal cohort (n=96) could be explained by poor 
pregnancy outcome characteristic of PE.  These two cohorts had 80 combined 
maternal-fetal pairs.  A sample of approximately 10 ml maternal whole blood 
was drawn from antecubital fossa veins and up to 5 ml fetal cord blood 
samples were collected at delivery.  Fetal cord blood samples collected from 
54 healthy pregnancies (Mixed Ancestry) were used as the control cohort.  
Whole blood and cord blood samples were collected in blood collection tubes 
containing the anti-coagulant ehtylenediaminetetraacetic (EDTA) (Becton, 
Dickson and Company, New Jersey, USA) and stored at -20°C until DNA 
extraction.   
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DETAILED EXPERIMENTAL PROCEDURES 
 
 
Genomic DNA 
Isolation 
 
PCR Amplification of Core Promoter Region 
and Exons 1 – 13 of ANXA2 gene 
 
Genotyping: 
 
Multiphor SSCP/HD Analysis 
 
Semi-automated DNA Sequencing 
 
RFLP Analysis 
 
     Statistical Analysis 
 
Figure 2.1 Overview of methods that were employed in this study. 
 
2.2 Genomic DNA Isolation from Whole Blood Samples 
 
Genomic DNA was extracted from whole blood from 120 women and 96 
offspring diagnosed with PE, as well as 54 healthy control individuals using 
the Miller et al. (1988) protocol (Appendix B).  This cohort included 80        
pre-eclamptic maternal-fetal pairs.  In those fetal samples of low volume, DNA 
were extracted from 300 µl cord blood using the Pure Gene®DNA isolation Kit 
(Gentra Systems™, Minneapolis, USA) (Appendix B).  All DNA samples were 
finally diluted in 50 µl TE buffer.   
 
27 
 
2.2.1 Quantification of Isolated Genomic DNA 
 
Genomic DNA samples were gently shaken for 20 minutes on a vortex prior to 
quantification, using the NanoDrop® ND-100 Spectrophotometer (Rockland, 
Delaware, USA).  DNA samples were diluted with dH2O according to their 
individual concentrations to a final concentration of 30 ng/µl.  These dilutions 
were used for PCR amplification as described in section 2.3.2.    
 
2.3 Polymerase Chain Reaction (PCR) 
 
2.3.1 Primer Design 
 
The ANXA2 gene reference sequence (accession number: NM_001002858) 
was obtained from NCBI Entrez Nucleotides Database 
(http://www.ncbi.nlm.nih.gov/nucleotide/, January 2008).  All primers were 
designed using Integrated DNA Technologies Software, Primer Quest 
(http://www.idtdna.com) (Figure 2.2).  The NCBI Basic Local Alignment 
Search Tool (BLAST) (http://www.ncbi.nlm.nih.gov/BLAST/) was used to 
examine primer specificity sequence similarity.  PCR amplification of the three 
intronless pseudogenes reported for the ANXA2 gene, along with other genes 
with high sequence similarity to the ANXA2 gene was prevented by designing 
primers flanking the coding regions of the gene.   
 
Characteristics of the designed primers are presented in Table 2.2.  Primers 
were also designed to amplify the 5‟ promoter area of the ANXA2 gene, while 
a mutagenic primer was designed for exon 9.   
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Figure 2.2 Schematic diagram of the ANXA2 gene indicating primer pairs 
relative to the exons and introns.  Abbreviations: ATG, start codon; F, forward; 
R, reverse; TGA, stop codon. 
 
2.3.1.1 Primer Design for Core Promoter Region and Exon 1 
 
Since the translation start site (ATG) for the ANXA2 gene is located within 
exon 2, exon 1 was considered as part of the promoter.  A core promoter 
region of approximately 600 bp for the ANXA2 gene was selected and 
overlapping primers were designed (http://www.idtdna.com).  Three primer 
pairs were designed to amplify fragments of approximately 300 bp, since 
fragments smaller than 400 bp are most ideal for resolution on the Multiphor 
SSCP/HD system.   Primers F1b and R1b amplified the entire exon 1 and this 
amplicon thus overlapped with the F1a/R1a amplicon (3 bp) (Figure 2.3).   
 
 
 
 
 
 
8 9 10 11 12 13 7 
F7 R7 F9 R9 F8 R8 F10 R10 F11 R11 F12 R12 F13 R13 
F1a R1a 
1 3 4 5 6 
F1b R1b F2 R2 F3 R3 F4 R4 F5 R5 F6 R6 P1F P1R 
 Exonic Region 
Intronic Sequence 
2 
ATG 
TGA 
5’ 
3’ 
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ggatcctggctcccggctttggcctcccagcccaggctcggggcttcctggcc
ctcggaggccggggcgggccaggctttgcagcacagggcgaatctccctccct
ccccgggcgccccccgggaactggcggccagaggttaagctgacatgtttgca
gacggtaatggggcgctggatgccaacagccccagctcaggggagtccagatt
tatgtttcttggaacaattctttcctccattgcattaacgccaaaaaaaaaaa
aaaaaaaaaaaaaacacttaatcaagcccagagtctactactaaagtcttgtt
aatttattaacccaagccgaggctgagagctcgacgtggcacttaagaagtaa
aatgaggaaaggaggaagaaacggggtccctgtgggcctcggggcagcctcgg
ccgggctttctcggagggcagggccaggggcgctggggccgctcccgcgtggc
gcggctcgggagcgttccagggcgcggtccctgcgggccggcgggccggggtg
agtcacccctgacttggggtgggagcgggccgtgtaagggggaggcggggcgg
ggcggggcgggcctcgcctcgcctagggaggatgtggcgggtataaaagcccc
acccaggccagccggctctGCTCAGCATTTGGGGACGCTCTCAGCTCTCGGCG
CACGGCCCAGGTAAGCGGGGCGCGCCCTGCCCGCCCGCGATGGGCCGCCAGCT
AGCGGGGTGTGGAGACGCTGGGAAGAAGGgtacggcctggcagggaggccccg
gcaactggccccggaggccgtcgggggcagggggctgaagggacggccggcac
tggagagtctttggggagggggctcagggacaaggtgtttggggcaggggtga
ggggccaccggccctcgggccgggagggtgcagggcagaggtggtggggggtc
gggcttctctaagaagccctagcgggagcggggcgaggcggcgtggggagagg
ggcggagggaggccccgcattccagacgcgccaggcgccgccgaggcagggcg  
 
Figure 2.3 PCR amplification of promoter and exon 1 with three primer 
sets: Fragment P1 primer pair (indicated in green), fragment 1a primer pair 
(indicated in bold and underlined) and fragment 1b primer pair (indicated in 
blue).  Exon 1 is indicated in upper case. 
 
2.3.1.2 Mutagenic Primer Design for Exon 9 
 
A mutagenic forward primer for exon 9 was designed to include a restriction 
endonuclease recognition site for digesting with Tsp509I to genotype the 
intronic SNP c.589-5 C>T (Table 2.1) (Figure 2.4).   
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Table 2.1  Mutagenic primer sequences for the characterisation of SNP c.589-5 C>T. 
Primer Sequence (5’-3’) 
Annealing 
Temp (ºC) 
Amplicon 
Size (bp) 
Restriction 
Enzyme 
Fragments 
Sizes (bp) 
9MF gtagttaacttttcctggttggttgtaat 
54 209 Tsp509I 
C allele: 209 
9R gtccatgttgggatggagt T alelle: 182, 27 
 
atctgtgcctaaggaagactgcttgtgattaagacttttgacctaaatagtag
gtctctgcccatgtctgcagtataatcatctttcctcgtttggcattttgaat
gtgtagctttttttgttttttttgcatgacattttttttgacgttacattgga
tgtgtagttaacttttcctggttggttgtaatc/tgtagGATCTCTATGACGC
TGGAGTGAAGAGGAAAGGAACTGATGTTCCCAAGTGGATCAGCATCATGACCG
AGCGGAGCGTGCCCCACCTCCAGAAAGgtgggcactgtgctgagggagtctca
gtgccttggggccctggctggggcggctgggtggatgtccatgttgggatgga
gtctgccagaatgaggttctgtctccgcttggcac 
 
Figure 2.4    PCR amplification of exon 9 with mutagenic forward primer 
(indicated in red) and the original reverse primers (indicated in green). The 
SNP IVS8-5 (C/T) is indicated in yellow highlight.  The a-nucleotide 
highlighted in blue is a c-nucleotide in the original ANXA2 sequence. 
 
2.3.2 PCR Parameters and Programmes 
 
The standard polymerase chain reaction (PCR) contained 1X GoTaq Buffer 
(Promega, Madison WI, USA), 30 ng of genomic DNA, 1.5 to 2.5 mM MgCl2 
(Promega, Madison WI, USA) (Table 3), 200 μM dNTPs (dATP, dCTP, dGTP, 
dTTP) (Fermentas International Inc., Hanover, USA), 0.2 to 0.4 μM forward 
and reverse primers (Table 3), 0.5 to 1.0 U of GoTaq Polymerase enzyme 
(Promega, Madison WI, USA) (Table 2.3), and the appropriate amount of 
ddH2O to reach a final reaction volume of 50 μl.  PCR reactions were 
performed using GeneAmp® PCR Systems 2700 (Applied Biosystems, 
California, USA).  The standard PCR cycle consisted of initial denaturation at 
95˚C for 3 minutes, followed by 35 cycles of denaturation at 95˚C for              
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20 seconds, annealing at the Ta for the specific PCR primers sets (Table 2.2) 
for 30 seconds, elongation at 72˚C for 30 seconds and a final elongation at 
72˚C for 5 minutes.   
 
Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich®, Steinheim, Germany) to a final 
concentration of 5% was added to the reaction mix of amplicon 1b, containing 
exon 1 and amplicon P1, containing the majority of the ANXA2 5‟UTR, in 
order to successfully optimise the reaction and increase the yield of the PCR 
product (Table 2.3).  Betaine (Sigma-Aldrich®, Steinheim, Germany) (final 
concentration of 0.5 M) was added to the reaction mix of the amplicon 
containing exon 6 to optimise and improve its amplification (Table 2.3).   
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Table 2.2 Oligonucleotide primers used for the amplification of relevant exons 
in the ANXA2 gene.  
Position Primer Sequence (5’-3’) 
Tm 
(ºC) 
Ta 
(ºC) 
Product  
Size (bp) 
5‟UTR 
P1F 
P1R 
ctttgcagcacagggcgaat 
acagggaccccgtttcttcct 
59 
60 
61 328 
5‟UTR/ 
Exon 1 
1aF 
1aR 
taacccaagccgaggctgag 
cgccgagagctgagagcgt 
60 
62 
58 366 
Exon 1 
1bF 
1bR 
ctgctcagcatttggggacg 
cccgctagggcttcttagaga 
59 
58 
62 329 
Exon 2 
2F 
2R 
tcgctgtgcttcagagtaaag 
cttccttagatgtacaaggatag 
55 
50 
54 216 
Exon 3 
3F 
3R 
tacctacctagttacctagtatg 
ccaacgtatggcgatttgag 
50 
54 
56 325 
Exon 4 
4F 
4R 
cttgacaccttctatgtaagcc 
cgcatgagagccacaattca 
53 
56 
54 261 
Exon 5 
5F 
5R 
ggtcaaagactcacaacctgc 
actgaaaatcaccaaattacactcaga 
56 
55 
54 312 
Exon 6 
6F 
6R 
ggatgctaacagacccaatc 
actaatgcaggcatcttagcc 
56 
55 
54 302 
Exon 7 
7F 
7R 
ctgttctgcttctcagagtc 
aggggatttagttaattcactcc 
53 
52 
55 273 
Exon 8 
8F 
8R 
taaataatggcgtacatggactg 
ggagtcatttgtcacacagag 
53 
53 
55 246 
Exon 9 
9F 
9R 
tctgcagtataatcatctttcctc 
actccatcccaacatggac 
52 
54 
54 305 
Exon 10 
10F 
10R 
ctaagctcctaggatgctgtg 
attaacaggatggccatctgtc 
55 
55 
55 300 
Exon 11 
11F 
11R 
ccattgcattaggtcacttctg 
catccatgaatcaaggag 
54 
47 
54 260 
Exon 12 
12F 
12R 
gatgctcaacctgtagacgc 
tcatcattctgccaggccac 
56 
58 
56 279 
Exon 13 
13F 
13R 
tgtgcgttgaggctacttctg 
gggactgttattcgcaagctg 
57 
56 
54 233 
Tm = Melting Temperature ; Ta = Annealing Temperature 
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Table 2.3 Final primer, Taq Polymerase, MgCl2, DMSO and Betaine 
concentrations in the PCR reaction for the amplification of the ANXA2 gene. 
Amplicon 
Primers 
(μM) 
Taq 
(U) 
MgCl2 
(mM) 
DMSO 
(%) 
Betaine 
(M) 
P1 0.2 0.5 1.5 5 - 
1a 0.2 0.5 1.5 5 - 
1b 0.4 1.0 1.5 - - 
2 0.4 0.5 1.5 - - 
3 0.4 0.5 2.0 - - 
4 0.4 0.5 2.0 - - 
5 0.4 0.1 2.0 - - 
6 0.4 0.5 2.5 - 0.5 
7 0.4 0.5 1.5 - - 
8 0.4 0.5 1.5 - - 
9 0.4 0.5 2.0 - - 
10 0.4 0.5 1.5 - - 
11 0.4 1.0 2.0 - - 
12 0.3 0.5 1.5 - - 
13 0.3 0.5 1.5 - - 
 
2.3.2.1   Visualisation of PCR Products 
 
Amplification was confirmed by agarose gel electrophoresis on a 1.5% (w/v) 
agarose gel with 1X TBE buffer (Appendix C) containing 0.003% (v/v) 
Ethidium Bromide (Sigma-Aldrich Inc., St Louis, USA).  Five μl of Cressol 
(Appendix A) was added to 5 μl of the amplification product and loaded onto 
the agarose gels.  The products were resolved at 120 Volts for 45 minutes in 
1X TBE buffer (Appendix C). A 100 bp molecular weight marker 
(O‟GenerulerTM, Fermentas International Inc., Hanover, USA) was used 
concurrently to estimate the size of the PCR products.  The gels were 
examined under UV light and photographed with the Multigenius Bio Imaging 
System (Syngene, Cambridge, UK). 
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2.4 Mutation Detection 
 
2.4.1 Multiphor Single Strand Conformational Polymorphism / 
 Heteroduplex (SSCP/HD) Analysis 
 
Amplicons were screened for conformational variation using Multiphor Single 
Strand Conformational Polymorphism/Heteroduplex (SSCP/HD) analysis 
(Liechti-Gallati et al., 1999) (Appendix B).  Three μl of each PCR product was 
mixed with 3 μl of fomamide-based loading dye (Appendix C) and denatured 
for 5 minutes at 95°C.  The mix was then quenched on ice, allowing the 
formation of stable homo- and heterodimers.  Three μl of this reaction mix was 
then loaded onto a Multiphor SSCP/HD gel, consisting of 12% (w/v) 
acrylamide-PDA gel mix (Appendix C), 10% (w/v) ammonium persulphate 
(APS) and N, N, N‟N‟-tetramethylethylene-diamine (TEMED).  Electrophoresis 
was performed at optimised temperatures, for optimised duration, at 355 Volts 
on the Pharmacia LKP 2117 MultiphorTM II Eletrophoresis System (Amersham 
Pharmacia Biotech, Amsterdam, UK) (Table 2.4).  
 
Following electrophoresis conformational bands on the Multiphor SSCP/HD 
gels (Appendix B) were visualised via a two-step 0.1% silverstaining method.  
Firstly the Multiphor SSCP/HD gel plates were stained in a 0.1% (w/v) Silver 
Nitrate (Appendix C) solution for 10 minutes, after which plates were washed 
with dH2O to remove excess solution from the gels.  The second step involved 
staining Multiphor SSCP/HD gels for 10 minutes with Developing Solution 
(Appendix C).  The gels were lifted onto clean Watmann filter paper and DNA 
fragments could be visualised immediately.    
 
2.4.2 Semi - automated DNA Sequencing 
 
Conformational variants detected on Multiphor SSCP/HD gels were 
subsequently characterised by bi-directional semi-automated DNA 
sequencing.  Successfully amplified PCR products chosen for semi-
automated DNA sequencing were purified using Sure Clean (Bioline. London, 
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UK) (Appendix B).  To ensure successful purification of the PCR products, 
concentrations were determined using the NanoDrop® ND-100 
Spectrophotometer (Rockland, Delaware, USA).  The Central Analytical 
Facility (Stellenbosch University, Stellenbosch, SA) performed all sequencing 
and electrophoresis reactions by using the BigDye®  Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, California, USA) followed by 
electrophoresis on the ABI 3130XL Genetic Analyzer (Applied Biosystems, 
California, USA).   
 
Sequences were analysed using BioEdit Sequence Alignment Editor Software 
v7.0.9.0 (Hall, 1999).  The sequences were aligned to the subsequent 
reference sequences (accession number: NM_001002858) obtained from 
NCBI Entrez Nucleotides Database (http://www.ncbi.nlm.nih.gov/nucleotide/, 
2008) using the ClustalW v1.4 program in BioEdit Sequence Alignment Editor 
Software Program and analysed for differences from the reference 
sequences. 
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Table 2.4 Detection methods used to screen the ANXA2 gene. 
Amplicon Detection Method 
Multiphor 
Temperature 
(ºC) 
Duration 
P1 
Multiphor SSCP/HD, Semi-automated 
DNA Sequencing 
17 3h 
1a 
Multiphor SSCP/HD, Semi-automated 
DNA Sequencing 
13 4h 
1b 
Multiphor SSCP/HD, Semi-automated 
DNA Sequencing 
9 3h45min 
2 
Multiphor SSCP/HD, RFLP, Semi-
automated DNA Sequencing 
4 3h20min 
3 
Multiphor SSCP/HD, Semi-automated 
DNA Sequencing 
17 3h30min 
4 
Multiphor SSCP/HD, 
Semi-automated DNA Sequencing 
13 2h 
5 
Multiphor SSCP/HD, RFLP, Semi-
automated DNA Sequencing 
4 3h20min 
6 Multiphor SSCP/HD 21 3h 
7 
Multiphor SSCP/HD, RFLP, Semi-
automated DNA Sequencing 
17 3h30min 
8 Multiphor SSCP/HD 21 3h15min 
9 
Multiphor SSCP/HD, RFLP, Semi-
automated DNA Sequencing 
13 3h30min 
10 
Multiphor SSCP/HD, RFLP, Semi-
automated DNA Sequencing 
5.5 3h 
11 
Multiphor SSCP/HD, Semi-automated 
DNA Sequencing 
17 3h15min 
12 
Multiphor SSCP/HD, RFLP, Semi-
automated DNA Sequencing 
17 3h30min 
13 
Multiphor SSCP/HD, RFLP, Semi-
automated DNA Sequencing 
13 3h15min 
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2.4.3 Restriction Fragment Length Polymorphism (RFLP) Analysis 
 
Genotypes were confirmed by Restriction Fragment Length Polymorphism 
(RFLP) analysis of the PCR products. The nature of the restriction fragments 
for each amplicon was determined (when the sequence variant abolished or 
created a restriction endonuclease recognition site) using 
restrictionmapper.org, http://insilico.ehu.es/restriction and BioEdit Sequence 
Alignment Editor Software v7.0.9.0 (Hall, 1999).  Restriction reactions 
consisted of 10 μl of the PCR product, 1X relevant restriction enzyme buffer 
(Table 2.5) and 5 U of the relevant restriction enzymes with added dH20 to 
bring the final reaction volume to 20 μl.  The incubation of the PCR products 
with relevant restriction enzymes was performed according to the 
manufacturers‟ recommendations for 16 hours (Table 2.5).  
 
Table 2.5 Restriction enzymes, buffers and incubation temperatures used 
for RFLP analysis. 
Exon Variant Buffer 
Restriction 
Enzyme 
Incubation 
Temperature 
Recognition 
Sequence (5’-3’) 
2 
c.-11-43 G>A B **Mbo II 37ºC  GAAGA(N)8^  
c.-11-13 A>T Tango **Rsa I 37ºC GT^AC 
9 
c.589-5 C>T 1 *Tsp509I 65ºC  ^AATT 
c.682+49 C>T 3 *Aci I 37ºC C^CGC 
10 c.683-56 G>A 3 *Bcl I 50ºC T^GATCA 
12 
c.934 G>A; 
p.Gly312Ser 
3 *BceA I 37ºC ACGGC(N)12^ 
13 
c.*1057 4 *Hph I 37ºC GGTGA(N)8^ 
c.975 C>T; 
p.Gly325Gly 
4 *Hph I 37ºC GGTGA(N)8^ 
 
Restriction Enzyme suppliers: 
*    New England Biolabs Inc., Beverly, USA 
**  Fermentas International Inc., Hanover, USA 
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2.4.3.1   Visualisation of Restriction Enzyme Digested Products 
 
The products of the restriction enzyme digestions were resolved on 3% (w/v) 
agarose gels with 1X TBE buffer (Appendix C) containing 0.003% (v/v) 
Ethidium Bromide (Sigma-Aldrich Inc., St Louis, USA).  A 100 bp molecular 
weight marker (O‟GenerulerTM, Fermentas International Inc., Hanover, USA) 
was used to estimate the size of the restriction fragments.  The gel 
electrophoresis was performed at room temperature and at 90 Volts for 
optimised duration.  An ultraviolet light (UV) system (Multi Genius Bio Imaging 
System, Syngene, Cambridge, UK) was used for visualisation of the DNA 
fragments (Fragment sizes are shown on the gels in the following section). 
 
2.4.4 Heteroduplex Single-Stranded Conformational Polymorphism 
(HEX-SSCP) Analysis 
 
Heteroduplex Single-Stranded Conformational Polymorphism (HEX-SSCP) 
analysis (Kotze et al., 1995) was used to screen and confirm genotyping in 
selected exons by preparing 12% (w/v) PAA gels (Appendix C) containing 
7.5% (w/v) urea, 1.5X TBE (Appendix C), 0.1% (w/v) ammonium persulphate 
(APS) and 0.1% (v/v) N, N, N‟N‟-tetramethylethylene-diamine (TEMED).   
 
PAA gels were cast, left to polymerise and the wells were cleaned with 1.5X 
TBE before the gel systems were assembled and filled with 1.5X TBE.  The 
HEX-SSCP gel system was kept at 4°C for approximately 1 hour before 
loading the PCR products.  PCR products (20 μl) mixed with 15 μl 
bromophenol blue loading dye (Appendix C) were denaturated at 95°C for    
10 minutes and cooled immediately on ice.  Fifteen μl of PCR product was 
loaded onto the PAA gels and eletrophoresis was performed at a constant 
temperature of 4°C at 250 Volts for 18 hours on the Hoefer SE 600 Basic Slab 
(30 cm) vertical apparatus. 
 
Following electrophoresis, gels were removed from the gel apparatus and 
stained in a 0.01% (v/v) Ethidium Bromide (Sigma-Aldrich Inc., St Louis, USA) 
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solution for 10 minutes and destained in dH2O for 3 minutes.  DNA fragments 
were visualised and photographed using an ultraviolet light (UV) system (Multi 
Genius Bio Imaging System, Syngene, Cambridge, UK).  
 
2.5 Statistical Analysis 
 
Allele and genotype frequencies were determined by counting, and tested for 
deviation from the Hardy-Weinberg Equilibrium (HWE) with Chi-square 
analysis in Tools For Population Genetic Analysis (TFPGA) Software v1.3 
(Miller, 1997).  Fischer‟s exact test was performed when less than five 
individuals of a certain genotype were observed.  Differences between the 
allele and genotype frequencies were verified in Microsoft® Office Excel 
(2003) by way of 2X2 and 2X3 contingency tables.  In order to determine a 
possible association between genetic variants in the ANXA2 gene and PE, an 
analog to Fischer‟s exact test and haplotype analysis were performed within 
Haploview, v3.31 (Barett et al., 2005).  P-values of less than 0.05 were 
considered significant. A LOD score ≥ 3 and a correlation coefficient (r2-value) 
of ≥ 0.4 were considered a significant indication of linkage disequilibrium (LD). 
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3 RESULTS 
 
3.1 Patient Demographics 
 
A total of 120 pre-eclamptic samples was available for genetic screening of 
the ANXA2 gene.  Clinical patient demographics for participants are shown in 
Table 3.1. Clinical patient information was obtained in the form of 
questionnaires completed by authorised hospital personnel (Appendix D). 
 
Table 3.1   Demographic features for the maternal study cohort.      
Patient demographic features Mean Range Normal 
Age (years) 22.5 14-43 n/a 
Gravidity 1.25 1-5 n/a 
Parity 0.2 0-3 n/a 
Systolic blood pressure (mmHg) 159.6 140-210 120 
Diastolic blood pressure (mmHg) 106.4 80-140 80 
Gestational age at complication (weeks) 29 25-34 n/a 
Gestational age at delivery (weeks) 30.25 22-38 38-40 
Fetal birth weight (grams) 1330 324-2496 Appendix E 
mmHg = Millimeter of Mercury 
 
Maternal patient demographics revealed that most mothers were primi-
gravidae patients, which was consistent with the mean maternal age observed 
(22.5 years).  As expected, systolic and diastolic blood pressure levels of pre-
eclamptic mothers were elevated compared to healthy pregnant mothers.  The 
median gestational age at complication was very early (29 weeks) and 
correlated with the mean gestational age at delivery (30.25 weeks), since 
clinical intervention was needed immediately to attempt saving mother and 
neonate.  Early delivery as a consequence of complication will affect the 
outcome of fetal birth weight directly, which explains the low fetal birth weight      
(1330 g) observed.  From the patient demographics it is evident that most 
cases were “early-onset” ie, PE was diagnosed after 20 weeks of pregnancy, 
but before 34 weeks, suggesting that this is a relatively „homogenous‟ clinical 
group. 
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3.2 Screening of the ANXA2 gene 
 
Conformational variants on the Multiphor SSCP/HD system were identified in 
ten of the 15 ANXA2 gene amplicons screened (Table 3.2). No variants were 
identified in exons 2, 3, 6, 7, 10 and 11 of the ANXA2 gene.  The sequence 
variants detected in the various regions of the ANXA2 gene, the PCR 
fragments they occurred in, their nature and reference number (if previously 
documented) are indicated in Table 3.2.  The nomenclature used to describe 
the ANXA2 gene and sequence variants in this study was according to the 
recommendations by the Human Genome Committee (HUGO), 
(http://www.genenames.org/guidelines.html) and the Human Genome 
Variation Society (HGVS), (http://www.hgvs.org/mutnomen/).  
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Table 3.2   Variants identified in the ANXA2 gene.   
Ref# = Reference number as retrieved from the Entrez SNP database, 
(http://www.ncbi.nlm.nih.gov/SNP/).  
Region Amplicon Variant Nature Ref# Reference 
5’UTR 
1a 
c.-442 (5‟UTR) C>G - NOVEL 
c.-191 (5‟UTR) G>C - NOVEL 
c.-189_-188ins(5‟UTR) GCCGG - NOVEL 
c.-135 (5‟UTR) C>G - NOVEL 
1b 
c.-92 (5‟UTR) A>T - NOVEL 
c.-31 (5‟UTR) T>C rs12904657 
NCBI SNP 
database 
Coding 
4 c.222; p.Ala74Ala C>T - NOVEL 
5 c.292; p.Val98Leu G>T rs1059688 
NCBI SNP 
database 
9 c.600; p.Asp110Asp C>T - NOVEL 
12 c.934; p.Gly312Ser G>A - NOVEL 
13 c.975;p.Gly325Gly C>T rs1244554 
NCBI SNP 
database 
Non-
coding  
1b c.-12+75 C>A rs12904756 
NCBI SNP 
database 
2 
c.-11-43 G>A rs11858864 
NCBI SNP 
database 
c.-11-13 A>T rs11855679 
NCBI SNP 
database 
c.48+67 C>T rs3743268 
NCBI SNP 
database 
5 
c.244-42 G>C - NOVEL 
c.244-76 C>G - NOVEL 
7 
c.449-17 G>A rs12898604 
NCBI SNP 
database 
c.528+38 C>T - NOVEL 
9 
c.589-5 C>T - NOVEL 
c.682+49 C>T - NOVEL 
10 c.683-56 G>A rs11633619 
NCBI SNP 
database 
13 
c.961-30 A>G - NOVEL 
c.961-24 C>G - NOVEL 
3’UTR 13 c.*1057 A>G - NOVEL 
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Figure 3.1   Schematic diagram (not drawn to scale) of the ANXA2 gene 
indicating positions of previously documented variants identified in this study 
(indicated in red), novel variants identified in this study (indicated in blue) and 
previously documented variants, not identified in this study (indicated in 
black).   
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Fifteen PCR fragments were used to screen the ANXA2 gene, including      
600 bp upstream into the 5‟UTR. Twenty-five sequence variants were 
identified in this study of which 15 were novel and ten previously documented 
(Figure 3.1). The variants were grouped according to their location and will be 
discussed accordingly.   
 
3.2.1 Variants in the ANXA2 5’UTR 
 
Five novel (c.-442 C>G, c.-191 G>C, c.-189_-188insGCCGG, c.-135 C>G and 
c.-92 A>T) and one previously reported (c.-31 T>C) variant were identified in 
the ANXA2 5‟UTR following Multiphor SSCP/HD analysis. 
    
Multiphor SSCP/HD analysis of amplicon 1a, containing part of the 5‟UTR and 
part of exon 1 (Appendix F, Figure 1a) revealed four novel variants, namely  
c.-442 C>G, c.-191 G>C, c.-189_-188insGCCGG and c.-135 C>G in the 
ANXA2 5‟UTR.  Sequencing electropherograms for SNPs c.-442 C>G,         
c.-191 G>C and c.-135 C>G are presented in Appendix F, Figure 1b.  All 
variants were genotyped by Multiphor SSCP/HD analysis, as the 
conformations were very distinctive.   
 
The DNA sequence representative of the novel 5 bp insertion 188 bp 
upstream of the translational start site (ATG) located in exon 2 was compared 
to the wild type sequence in Appendix F, Figure 2 to indicate the position and 
nature of this insertion. The c.-189_-188insGCCGG insertion revealed a 
unique conformation in the heteroduplex section of the gel.  The heterozygous 
status of the c.-189_-188insGCCGG insertion was more prevalent in the total 
maternal cohort (4.6%) compared to the fetal (1.2%) and control (1.9%) 
cohorts.  No individuals homozygous for the insertion were observed.  
 
Multiphor SSCP/HD analysis of amplicon 1b, encompassing exon 1 (Appendix 
F, Figure 3), revealed one novel SNP c.-92 A>T and one previously 
documented SNP c.-31 T>C (dbSNP: rs12904657).  These two SNPs are 
45 
 
localized upstream of the ATG within exon 2 and were therefore classified as 
variants located in the ANXA2 5‟UTR.   
 
No restriction endonuclease recognition sites could be found to confirm SNP 
c.-31 T>C.  Several patient and control individuals were subsequently 
subjected to HEX-SSCP analysis (Figure 3.2) to confirm genotypes observed 
on the Multiphor SSCP/HD system, since the conformations were not always 
clear and easy to distinguish from each other.   In Figure 3.2 conformations 2, 
5 and 7 as allocated on the Multiphor SSCP/HD gels appeared similar on the 
HEX-SSCP gels, although the DNA sequences revealed that these are 
different from each other.  Multiphor conformations 1, 4 and 6 appeared 
identical on the HEX-SSCP gels, but were in actual fact different according to 
the DNA sequencing results.  Genotypes for SNP c.-31 T>C were therefore 
allocated according to Multiphor typings.  In contrast, Multiphor conformations 
for variant c.-92 A>T were clear and were therefore used to genotype the 
patient and control cohorts. 
 
 
 
Figure 3.2   HEX-SSCP analysis of specific conformations observed with 
Multiphor SSCP/HD analysis. Lane 1 = conformation 1; lanes 2-6 = 
conformations 2 and 5; lanes 7-9 = conformations 3 and 4; lane 10 = 
conformation 6; lanes 11, 12 = conformation 7 according to Multiphor 
SSCP/HD analysis. 
 
 
 
 
  1         2        3       4        5       6       7       8        9       10      11     12     
13     14 
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3.2.2 Coding Variants 
 
Three novel (c.222 C>T; p.Ala74Ala, c.600 C>T; p.Asp110Asp and               
c.934 G>A; p.Gly312Ser) and two previously reported (c.292 G>T; 
p.Val98Leu and c.975 C>T; p.Gly325Gly) variants were identified within the 
coding regions of the ANXA2 gene following Multiphor SSCP/HD analysis.  
 
Multiphor SSCP/HD analysis of the amplicon containing exon 4, revealed a 
novel synonymous exonic SNP at amino acid position 74 (c.222 C>T; 
p.Ala74Ala) (Appendix F, Figure 5a).   No restriction enzyme digest was 
performed to confirm genotypes observed on Multiphor SSCP/HD gels, since 
all three variant conformations detected, were subjected to semi-automated 
DNA sequencing (Appendix F, Figure 5b).  Three heterozygous C/T control 
individuals were observed (5.7%), but the variant allele was absent from 
maternal and fetal patient cohorts.  
 
One previously documented exonic SNP c.292 G>T; p.Val98Leu (dbSNP: 
rs1059688) was detected following bi-directional DNA sequencing of the 
conformational variants identified by Multiphor SSCP/HD analysis of the 
amplicon containing exon 5 (Appendix F, Figures 6a and 6b).  The non-
synonymous exonic SNP Val98Leu is responsible for a change from Valine to 
Leucine at amino acid position 98, which are both hydrophobic amino acids 
with non-polar side chains.  None of the patient or control individuals were 
found to be homozygous for this SNP.   
 
Multiphor SSCP/HD analysis of the amplicon containing exon 9, revealed one 
novel synonymous SNP c.600 C>T; p.Asp110Asp (Appendix F, Figure 8a).  
SNP c.600 C>T; p.Asp110Asp occurred at a very low frequency, as only one 
heterozygous individual was detected in the control cohort (1.9%).  Semi-
automated DNA sequence analysis was employed to confirm the genotype 
(Appendix F, Figure 8b).   
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Multiphor SSCP/HD analysis of the amplicon containing exon 12 revealed the 
presence of a novel exonic SNP c.934 G>A; p.Gly312Ser (Appendix F, Figure 
10).  This non-synonymous exonic SNP is responsible for a change from the 
amino acid glycine, a hydrophobic amino acid with non-polar side chains to 
serine, which has polar side chains.  Genotypes determined on the Multiphor 
SSCP/HD system were confirmed with a BceAI (New England Biolabs, USA) 
restriction enzyme digest (Figure 3.3).  Digestion fragments of 216 bp and     
62 bp resolved on a 3% agarose gel, represented homozygous status for the 
A allele, while three fragments of 187 bp, 62 bp and 26 bp represented 
homozygous status for the G allele.  This SNP was detected at a very low 
frequency in the total maternal patient group (2.5%), the total fetal patient 
group (3.4%) and the control group (7.7%).   
 
                      
 
Figure 3.3   BceAI restriction enzyme analysis of c.934 G>A; p.Gly312Ser in 
the amplicon containing exon 12 resolved on a 3% (w/v) agarose gel.  Lane 1 
= 100 bp molecular weight marker (O‟GenerulerTM, Fermentas); lane 2 = GA, 
lane 3 = GG.  
 
Multiphor SSCP/HD analysis of the amplicon containing exon 13 revealed one 
previously documented SNP c.975 C>T; p.Gly325Gly (dbSNP: rs12442554) 
(Appendix G, Figure 11).  This synonymous SNP (c.975 C>T; p.Gly325Gly) 
located at amino acid position 325 is responsible for a silent mutation.   
1          2          3 
216 bp 
187 bp 
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Conformation 4 could not be distinguished from conformation 1 on Multiphor 
SSCP/HD gels and a HphI (New England Biolabs, USA) restriction enzyme 
digest was used to confirm SNP c.975 C>T; p.Gly325Gly and thereby 
differentiate between these conformations and minimise mistyping of this 
locus (Figure 3.4).  Digestion fragments of 60 bp and 173 bp resolved on a 
3% agarose gel indicated individuals homozygous for the C allele.  Three 
fragments 60 bp, 62 bp and 111 bp indicated individuals homozygous for the 
T allele.   
 
         
 
Figure 3.4   HphI restriction enzyme analysis of c.975 C>T; p.Gly325Gly in 
the amplicon containing exon 13 resolved on a 3% (w/v) agarose gel. Lane 1 
= 100 bp molecular weight marker (O‟GenerulerTM, Fermentas); lanes 2, 3, 4 
= CC, lane 5 = CT.  
 
3.2.3 Intronic Variants 
 
Following Multiphor SSCP/HD analysis, seven novel (c.244-42 G>C,          
c.244-76 C>G, c.528+38 C>T, c.589-5 C>T, c.682+49 C>T, c.961-30 A>G, 
c.961-24 C>G) and six previously identified (c.-12+75 C>A, c.-11-43 G>A,     
c.-11-13 A>T, c.48+67 C>T, c.449-17 G>A, c.683-56 G>A) variants were 
identified in the non-coding regions flanking the exons in the ANXA2 gene. 
 
One previously documented intronic SNP c.-12+75 C>A (rs12904756) within 
intron 1 was identified upon Multiphor SSCP/HD analysis of amplicon 1b, 
       1         2            3           4           5   
173 bp 
111 bp 
 60bp 
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containing exon 1 (Appendix F, Figure 3).  Multiphor conformations of this 
SNP were clear and therefore used to perform genotyping in the patient and 
control cohorts.    
 
Multiphor SSCP/HD analysis of the amplicon containing exon 2 revealed three 
previously documented DNA sequence variants viz, c.-11-43 G>A (dbSNP: 
rs11858864), c.-11-13 A>T (dbSNP: rs11855679), located within intron 1, and         
c.48+67 C>T (dbSNP: rs3743268) located within intron 2 (Appendix F, Figure 
4).    
 
RFLP analysis using the restriction enzymes MboII (Fermentas, Burlington, 
USA) and RsaI (Fermentas, Burlington, USA) confirmed the genotypes 
observed on the Multiphor SSCP/HD gels for the following two variants;        
c.-11-43 G>A and c.-11-13 A>T (Figure 3.5).  In the presence of the              
c.-11-43 G>A SNP, MboII cleaved the A allele into two fragments (34 bp and 
182 bp) while individuals homozygous for the G allele could be identified by 
fragments of 22 bp and 194 bp on 3% agarose gels.  RsaI digestion for variant 
c.-11-13 A>T, yielded fragment sizes of 12 bp, 52 bp and 152 bp, and these 
products were visualised on 3% agarose gels for the identification of  the A 
homozygosity status.  Individuals homozygous for the T allele could be 
identified by fragments of 12 bp and 204 bp.  SNP c.48+67 C>T was 
genotyped according to Multiphor typings, since no restriction endonuclease 
recognition sites could be identified. The homozygous status of the variant 
allele of SNP c.-11-43 G>A occurred at a higher frequency in the control 
cohort (46.3%) compared to the maternal (36.4%) and fetal cohorts (36.2%).   
The frequency of SNP c.-11-13 A>T in the maternal and fetal patient and 
control cohorts were identical to that observed for SNP c.-11-43 G>A.  This 
could potentially be explained by LD between these two closely-located SNPs 
in this population.  The variant allele T of SNP c.48+67 C>T was only 
observed in one heterozygous patient in the maternal group, at a frequency of 
0.9% but was absent in the control and fetal groups.   
 
50 
 
                           
  
 
 
 
 
Figure 3.5   MboII and RsaI restriction enzyme analysis of c.-11-43 G>A and 
c.-11-13 A>T in the amplicon containing exon 2, resolved on a 3% (w/v) 
agarose gel. Lane 1 = 100 bp molecular weight marker (O‟GenerulerTM, 
Fermentas); lanes 2, 3 = GG; lanes 4, 5 = GA; lanes 6, 7 = AA; lanes 9, 10 = 
AT; lanes 11, 12 = AT, lanes 13, 14 = TT. 
 
Two novel intronic SNPs (c.244-76 C>G and c.244-42 G>C) were detected  
within intron 4 following bi-directional DNA sequencing of the conformational 
variants identified by Multiphor SSCP/HD analysis of the amplicon containing 
exon 5 (Appendix F, Figure 6).  None of the patient or control individuals was 
found to be homozygous for any of these SNPs. 
 
Multiphor SSCP/HD analysis of the amplicon containing exon 7 revealed a 
previously documented SNP c.449-17 G>A (dbSNP: rs12898604) and novel 
SNP c.528+38 C>T within introns 6 and 7, respectively (Appendix F, Figure 
7).  Genotypes on the Multiphor SSCP/HD gels could be distinguished with 
certainty and were thus assigned according to Multiphor typings.  
 
Multiphor SSCP/HD analysis of the amplicon containing exon 9 revealed two 
novel SNPs c.589-5 C>T and c.682+49 C>T within introns 8 and 9, 
respectively (Appendix F, Figure 8).  The Multiphor conformational variant 
used to distinguish individuals heterozygous for the SNP c.589-5 C>T could 
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not always be genotyped with certainty.  All samples were therefore subjected 
to a Tsp509I (New England Biolabs, USA) restriction enzyme digest and 
visualised on 3% agarose gels to identify and confirm genotypes (Figure 3.6).  
In the presence of the T allele Tsp509I cleaved the amplicon into two smaller 
restriction digestion fragments (27 bp and 182 bp) and individuals 
homozygous for the C allele could be identified by an uncut fragment of 209 
bp.   
 
AciI (New England Biolabs, USA) restriction digest, resolved on 3% agarose 
gels confirmed the SNP c.682+49 C>T by revealing fragments 105 bp and 
200 bp in size (representing homozygosity for the T allele).  Homozygosity for 
the C allele was reflected by three fragments (31 bp, 74 bp, 200 bp) (Figure 
3.7).     
 
          
 
Figure 3.6   Mutagenic primers amplified a 209 bp fragment for a Tsp509I 
restriction enzyme digest that enabled identification of SNP c.589-5 C>T in 
the amplicon containing exon 9 on a 3% (w/v) agarose gel.  Lane 1 = 100 bp 
molecular weight marker (O‟GenerulerTM, Fermentas); lane 2 = undigested 
fragment (209 bp), lanes 3, 4, 6 = CC, lanes 5, 7 = CT.    
 
 
 
 
 
209 bp 
182 bp 
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Figure 3.7   AciI restriction enzyme analysis of c.682+49 C>T in the amplicon 
containing exon 9 resolved on a 3% (w/v) agarose gel.  Lane 1 = 100 bp 
molecular weight marker (O‟GenerulerTM, Fermentas); lanes 2 = CT, lanes 3, 
4 = CC, lane 5 = undigested fragment (305 bp).   
  
Multiphor SSCP/HD analysis of the amplicon containing exon 10 revealed 
several unique conformations at several temperatures during optimization, but 
once genotyped at large scale no variation could be detected.  Running 
temperatures and duration, the amount of PCR product and loading dye were 
adjusted, but nonetheless no variation could be detected. The different 
conformations identified during optimization were therefore subjected to bi-
directional DNA sequencing, which revealed the presence of the previously 
documented SNP c.683-56 G>A (dbSNP: rs11633619) within intron 9 
(Appendix F, Figure 9).   
 
This locus was genotyped using a restriction enzyme for digestion with BclI 
(New England Biolabs, USA) of the amplicon containing exon 10 (Figure 3.8). 
Digestion fragments 21 bp, 49 bp and 230 bp, resolved on 3% agarose gels, 
indicated homozygosity for the A allele. Homozygous status for the G allele 
could be recognized by fragments of 21 bp and 279 bp. 
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Figure 3.8   BclI restriction enzyme analysis of c.683-56 G>A in the amplicon 
containing exon 10 resolved on a 3% (w/v) agarose gel.  Lane 1 = 100 bp 
molecular weight marker (O‟GenerulerTM, Fermentas); lane 2 = undigested 
fragment (300 bp), lanes 3, 6, 16 = GA, lanes 4, 5, 7-12, 14, 17 = GG; lanes 
13, 15, 18 = AA. 
 
Multiphor SSCP/HD analysis of the amplicon containing exon 13 revealed two 
novel intronic SNPs c.961-30 A>G and c.961-24 C>G within intron 12 
(Appendix F, Figure 11).  SNP c.961-30 A>G was genotyped according to 
Multiphor typings, which could easily be distinguished from other 
conformations.  Genotypes for SNPs c.961-24 C>G was confirmed by semi-
automated DNA sequencing (Appendix F, Figure 11b), since only one control 
sample showed heterozygous status. No homozygous status for these two 
SNPs was identified. 
 
3.2.4  Variants in the ANXA2 3’UTR 
 
Multiphor SSCP/HD analysis of the amplicon containing exon 13 revealed the 
novel SNP c.*1057 A>G in the ANXA2 3‟UTR (Appendix F, Figure 11).  SNP 
c.*1057 A>G is located 37 bp downstream the stop codon in the 3‟UTR in 
exon 13. Only one heterozygous genotype was observed in the maternal 
patient cohort (0.9%), indicating that this SNP occurred at a very low 
frequency in this population.   
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3.3 Statistical Analysis 
 
Allele and genotype frequencies were determined for all loci in the ANXA2 
gene, and analysed for deviation from the Hardy-Weinberg Equilibrium (HWE) 
with Chi-square analysis in Tools For Population Genetic Analysis (TFPGA) 
Software v1.3 (Miller, 1997).  The frequencies for 23 of the 25 variants 
identified in the ANXA2 gene were in HWE (Appendix G, Tables 1-12, 
together with the P-values).  P-values of less than 0.05 were considered as 
significant and are highlighted in red (Appendix G, Tables 1-12).   
 
Statistical significant associations between patient and control cohorts were 
determined by an analog to Fischer‟s exact test and verified by way of 2X3 
contingency tables in Microsoft® Office Excell (2003) and are presented in        
Appendix G, Tables 1-12.  Patient cohorts were subdivided into maternal and 
fetal patient cohorts and compared to a control group.  Patients were further 
stratified into subgroups according to their ethnicity, namely Mixed Ancestry 
and South African Black maternal and fetal groups.  P-values of less than 0.05 
were considered as significant and are highlighted in blue in Appendix G, 
Tables 1-12.  
 
3.3.1 Variants in the ANXA2 5’UTR 
 
Genotype and allele frequencies for four (c.-442 C>G, c.-191 G>C,                    
c.-189_-188insGCCGG and c.-135 C>G) of the six DNA sequence variants 
identified in the 5‟UTR, showed no deviation from HWE (P>0.05) in any of the 
maternal and fetal patient or control study cohorts.     
 
Genotype and allele frequencies for SNP c.-92 A>T in the total maternal 
cohort deviated from HWE (0.0431), however no deviation was observed in 
the total fetal and control cohorts, or any of the maternal and fetal subgroups 
(P>0.05).  The genotype distribution for SNP c.-31 T>C in all maternal, fetal 
and control study groups deviated from HWE (P<0.05).  
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No significant differences in genotype and allele frequencies were observed 
between maternal patient and control cohorts or the fetal patient and control 
cohorts for sequence variants c.-442 C>G, c.-191 G>C,                                      
c.-189_-188insGCCGG and c.-135 C>G.   
 
Statistical significance was observed at locus c.-92 A>T when comparing the 
total maternal patient group (p=0.039) and the Black fetal patient subgroup 
(p=0.019) to the control group.  The minor allele T for this SNP occurred at a 
higher frequency in the total (16.4%), Mixed Ancestry (15.9%) and Black 
(17.1%) maternal patient groups, compared to the control (7.8%) group.   
 
Statistical significant differences in genotype frequencies between the total 
maternal patient and control cohorts (p=0.039), total fetal patient and control 
cohorts (p=0.003) and Black fetal patient and control cohorts (p=0.007) were 
observed for SNP c.-31 T>C.  The variant allele C was present at a higher 
frequency in the total maternal patient cohort (62.1%), the Mixed Ancestry 
maternal patient cohort (61.4%) and the Black maternal patient cohort (63.4%) 
compared to the frequency observed in the control cohort (44.1%).  
 
3.3.2 Coding Variants 
 
Genotype and allele frequencies observed in the maternal, fetal and control 
study cohorts for all variants identified in the coding regions of the ANXA2 
gene were in HWE (P>0.05).  
 
Only one of the five exonic SNPs revealed a significant difference in genotype 
and allele frequencies between the patient and control study cohorts.  A 
significant difference in allele frequencies was observed between the total 
maternal and control cohorts (p=0.008), the Mixed Ancestry maternal and 
control cohorts (p=0.035) and the total fetal and control cohorts (p=0.019) for 
SNP c.222 C>T; p.Ala74Ala located within exon 4.   
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3.3.3 Intronic Variants 
 
Two variants (c.-12+75 C>A and c.244-76 C>G) identified in the non-coding 
regions of the ANXA2 gene showed deviation from HWE in certain subgroups.  
Genotype and allele frequencies for all the other DNA sequence variants 
identified in the non-coding regions of the ANXA2 gene showed no deviation 
from HWE (P>0.05) in the maternal and fetal patient or the control study 
cohorts.     
 
The genotype distribution for SNP c.-12+75 C>A deviated from HWE in the 
Black maternal patient group (0.0426), although none of the other study 
groups deviated from HWE at this locus.  Genotype and allele frequencies 
observed in the Mixed Ancestry fetal patient group for SNP c.244-76 C>G 
located within intron 4 deviated from HWE (0.0000).  One heterozygous C/G 
individual (2.3%) and one individual homozygous for the G allele (2.3%) were 
observed in the Mixed Ancestry fetal patient group at locus c.244-76 C>G.      
 
The only intronic loci to reveal a significant difference in genotype and allele 
frequencies between the maternal patient and control and fetal patient and 
control cohorts were the variants c.244-76 C>G, c.449-17 G>A and              
c.589-5 C>T. 
 
A significant difference was identified between the Black maternal patient 
group and the control group (p=0.018) at locus c.244-76 C>G.  Statistical 
significant differences were observed in genotype and allele frequencies 
between the Black maternal patient group and the control group (p=0.032), 
along with a significant difference in allele frequency between the Black fetal 
patient and control group (p=0.030) at locus c.449-17 G>A.    
 
Marginal association with PE was identified at locus c.589-5 C>T in the total 
fetal patient cohort (p=0.041), Mixed Ancestry fetal patient cohort (p=0.041) 
and the Black fetal patient cohort (p=0.041), but the variant allele T was 
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absent in the control cohort.  No significant differences was detected between 
maternal and control cohorts.   
 
3.3.4 Variants in the ANXA2 3’UTR 
 
Genotype and allele frequencies for SNP c.*1057 A>G identified in the 3‟UTR 
of the ANXA2 gene showed no deviation from HWE (P>0.05) in the maternal 
and fetal patient or the control study cohorts.     
 
No significant differences in genotype and allele frequencies were observed 
between any of the patient and control cohort for SNP c.*1057 A>G.  
 
3.4 Comparison of the Genotype and Allele Frequencies in 
 Different Ethnic Populations 
 
Genotype and allele frequencies in European, Asian and Sub-Saharan African 
populations of nine previously documented loci identified in this study, were 
compared to the frequencies observed in this study population          
(Appendix H, Table 1).  These frequencies were retrieved on 27 July 2009 
from the Entrez SNP database, (http://www.ncbi.nlm.nih.gov/SNP/). 
 
3.5 Haplotype Analysis 
 
Haplotype analyses were performed on maternal and fetal patient cohorts 
independently within each subgroup (Mixed Ancestry and Black) within 
Haploview, version 3.31 (Barett et al., 2005).  SNP c.-31 T>C (marker 6) 
located within exon 1 was excluded from haplotype analysis, because of its 
deviation from the HWE in both patient and control cohorts (P<0.05).  All loci 
included in haplotype analysis are presented in Appendix H, Table 2.  Results 
of the analysis on the Mixed Ancestry and Black maternal patient cohorts 
using the four gamete rule (Wang et al., 2002) are presented in Table 3.3.  
The same analyses were replicated on the Mixed Ancestry and Black fetal 
patient cohorts and the results are presented in Table 3.4.   
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In a previous study by Bogdanova et al. (2007) a haplotype in the ANXA5 
promoter was identified in a German population and associated with RPL, 
another poor placental disease like PE.  Variants identified in the 5‟UTR of the 
ANXA2 gene were subjected to haplotype analysis in attempt to identify a 
similar haplotype in the promoter region of ANXA2 that could possibly be 
associated with PE.   
 
3.5.1 Maternal and Control Cohorts 
 
The four gamete rule within Haploview identified two intronic SNPs,               
c.-11-43 G>A and c.-11-13 A>T, indicating a significant level of LD between 
the loci in both the Mixed Ancestry and Black maternal patient cohorts.  LD 
between these two SNPs was demonstrated by D‟ value = 1.0, LOD score = 
51.05, r2 value = 1.0 in the Mixed Ancestry maternal patient subgroup and by 
D‟ value = 1.0, LOD score = 43.56, r2 = 1.0 in the Black maternal patient 
subgroup (indicated in red) (Table 3.3).  LD was absent from other haplotype 
blocks identified in this analysis.   
 
Table 3.3 Haplotype analysis of the maternal patient and control cohorts 
employing the four gamete rule.    
Study 
Haplotype 
Blocks 
1 2 3 4 
Cohort Markers 2-7 8-9 10-19 20-25 
 D’ 1.0 1.0 1.0 1.0 
Mixed 
Ancestry 
LOD 0.13 51.05 0.01 0.11 
 r2 0.001 1.0 0.0 0.005 
Study 
Haplotype 
Blocks 
1 2 3 4 
Cohort Markers 1-7 8-9 11-16 17-25 
      
 D’ 0.383 1.0 1.0 1.0 
South African 
Black 
LOD 0.21 43.56 0.03 0.01 
 r2 0.015 1.0 0.0 0.0 
 
59 
 
3.5.2 Fetal and Control Cohorts 
 
The four gamete rule revealed a significant level of LD between SNPs          
c.-11-43 G>A and c.-11-13 A>T, in both the Mixed Ancestry fetal (D‟ value = 
1.0, LOD score = 47.21 and r2 value = 1.0) and Black fetal (D‟ value = 1.0, 
LOD score = 40.19 and r2 value = 1.0) patient subgroups (indicated in red) 
(Table 3.4).  These previously identified intronic SNPs are located 30 bp from 
each other within intron 1.  LD was absent from the other haplotype blocks 
identified in the analysis of the fetal patient and control cohorts. 
 
Table 3.4 Haplotype analysis of the fetal patient and control cohorts 
employing the four gamete rule.    
Study 
Haplotype 
Blocks 
1 2 3  
Cohort Markers 1-7 8-9 11-25  
 D’ 1.0 1.0 1.0  
Mixed 
Ancestry 
LOD 0.11 47.21 0.01 
 
 r2 0.001 1.0 0.0  
Study 
Haplotype 
Blocks 
1 2 3 4 
Cohort Markers 2-7 8-9 11-15 16-25 
 D’ 1.0 1.0 1.0 1.0 
South 
African 
Black 
LOD 0.07 40.19 0.18 0.0 
 r2 0.001 1.0 0.003 0.0 
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3.6 In Silico Analysis  
 
3.6.1 Promoter Variants 
 
In silico analysis of the variants identified in the 5‟UTR was                   
performed using the internet based transcription factor binding site             
prediction databases TESS, (http://www.cbil.upenn.edu/cgi-bin/tess),                     
MatInspector (http://www.genomatrix.de/cgi-bin/matinspector_prof/), 
AliBaba2.1 (http://www.gene-regulation.com/pub/programs/alibaba2/index.html) 
and JASPAR CORE (http://jaspar.genereg.net/).  The results of these 
predictions are presented in Table 3.5. 
 
The putative transcription factor binding sites predicted to be created or 
abolished in the presence of each variant were compared between the 
different databases.  The concurrent results from more than one database 
would increase the strength of any predictions.  In this study, the abolishment 
of a putative Sp1 site in the presence of the c.-191 G>C SNP as predicted by 
TESS and AliBaba2, was the only corresponding results between the four 
databases employed. Other transcription factor binding sites that were 
frequently predicted to be abolished in the presence of variants identified in 
the 5‟UTR were the sites NF-1 and BRCA1, which will be included in the 
discussion.  
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Table 3.5 Putative transcription factor binding sites in the promoter region of the ANXA2 gene, predicted to be created or 
abolished in the presence of each of the six variants identified in the 5‟UTR.     
 
 
TESS MatInspector Alibaba2 JASPAR CORE 
Creates Abolished Creates Abolished Creates Abolished Creates Abolished 
c.-442 C>G 
CTCF,CAC1, 
CAC2, 
CACCCC 
binding factor 
T-Ag           
Gal4 
- - - - M2F1_1-4 - 
c.-191 G>C - 
ETF (2X) 
CP1,LSF,Sp1, 
NF-S 
GCF,GAL4 
XCPE1 
PLAG1,ZF9 
EGR1,KKLF 
WT1 
NF-1 (2X)  
Sp1 
- - 
c.-189_-188insGCCGG 
 
- 
 
 
- 
 
XCPE1 
KLF6,Sp2 
MAZ 
- 
WT1,Sp1 (2X) 
ETF, appaB, 
AP,1ph 
NF-1,SRY 
Sp1,YY1,AP 
TFAP2A (2X)  - 
c.-135 C>G 
T-Ag,Sp1      
LBP-1 
- - - 
AP-2alpha  
c-Myc 
- - BRCA1 
c.-92 A>T RAF 
Sp1           
ABF1 
DMTE - - - - - 
c.-31 T>C - TEF2 - 
TIEG       
BKLF 
Sp1 - - 
BRCA1 
CREB1 
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3.6.2 Coding Variants 
 
Five loci were identified with Multiphor SSCP/HD analysis within the coding 
regions of the ANXA2 gene.  SNP c.*1057 A>G is located in exon 13, 37 bp 
downstream of the stop codon and was therefore excluded from in silico 
analysis.  
 
Exonic SNPs were analysed using the software program SIFT (Sorting 
Intolerant From Tolerant) (http://blocks.fhcrc.org/sift/SIFT/html) to determine 
the putative effect of amino acid substitutions on the function of the annexin II 
protein.  Of the six SNPs analysed c.934 G>A; p.Gly312Ser was predicted to 
affect protein function with a score of 0.01, a normalized probability              
score < 0.05 was considered to be deleterious. PMUT 
(http://mmb2.pcb.ub.es:8080/PMut/), a software program based within MMB 
(Molecular Modeling and Bioinformatics Group) (http://mmb.pcb.ub.es/) 
confirmed the prediction obtained with SIFT, in that SNP c.934 G>A; 
p.Gly312Ser might have a possible pathological effect on the function of 
annexin II.  PMut predicted this with a NN output value = 0.8816, where an 
output > 0.05 was considered as pathological.   
 
Above mentioned exonic SNPs were analyzed using internet based program 
ESE Finder version 3.0 (http://rulai.cshl.edu/tools/ESE/) (Cartegni et al., 
2002).  The creation of an exonic splicing enhancer (ESE) motif was predicted 
in the presence of the variant T allele at the c.292 G>T; p.Val98Leu locus.  
This software program is based on the fact that SR (Serine/Arginine) proteins 
such as SF2/ASF, SRp40, SRp55 AND SC35 are known to bind to these 
motifs (Smith et al., 2006; Wang et al., 2005b).   
 
3.6.3 Intronic Variants 
 
Thirteen variants identified in the non-coding regions of the ANXA2 gene were 
subjected to in silico analysis to predict their possible roles in alternative 
splicing.  The software program ASSP (Alternative Splice Site Predictor) 
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(http://www.es.embnet.org/~wang/asp.html) predicted that only one intronic 
variant, c.244-76 C>G could affect alternative splicing by the abolishment of 
an acceptor site in the presence of the variant allele G, this result however 
was not confirmed by the software program NetGene2 
(http://www.cbs.dtu.dk/services/NetGene2).  NetGene2 additionally predicted 
the abolishment of a donor site in the presence of the c.449-17 G>A variant 
allele A and the creation of an acceptor site in the presence of the              
c.961-30 A>G variant allele G.   
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4 DISCUSSION 
 
4.1 Genetic Data Analysis 
 
Sixteen of the 25 variants identified in the ANXA2 gene and the proximal 
promoter region are novel, of which five are located within the 5‟UTR, three 
are exonic, seven are intronic, and one is located within the 3‟UTR.  
Furthermore, significant associations were identified between four novel       
(c.-92 A>T, c.222 C>T; p.Ala74Ala, c.244-76 C>G and c.589-5 C>T) and one 
previously documented (c.449-17 G>A) variants and PE.     
 
Most variants in the human genome occur within intronic regions or the 
promoter area of genes (Haga et al., 2002; Hughes et al., 2003).  Results 
obtained in this study substantiate these findings as 13 of the 25 variants 
identified were located within non-coding regions, and only six variants 
identified in the 5‟UTR, five identified in the coding regions of the gene and 
one identified in the 3‟UTR.  Despite this knowledge, SNPs in the coding 
regions of genes have previously been considered as the most significant 
SNPs to investigate, as these SNPs were believed to be the ones to most 
likely have a functional effect.  Three of the five exonic SNPs identified in this 
study were synonymous SNPs which correlate with findings by Haga et al. 
(2002) that allele frequencies of silent mutations within coding regions of 
genes have been documented to be much higher than non-synonymous 
SNPs.   
 
Seven of the 25 variants identified in this study were responsible for C to T 
transitions, of which four formed CG dinucleotides.  This, however, was 
expected because of the mutability of CG dinucleotides, which are also known 
as mutation hotspots (Bird, 1987; Cooper and Youssoufian, 1987).   DNA 
methylation of CG dinucleotide sequences account for the conversion of 
cytosines to 5‟mC, which in turn become uracils upon deamination.  When the 
deaminated base has not been repaired, the uracil becomes a thymidine 
(Bird, 1987; Cooper and Youssoufian, 1987), resulting in a C to T transition.  
Improved understanding of mutational processes such as these hotspots, 
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could promote our knowledge of genetic processes such as replication, 
transcription and recombination, consequently contributing to our knowledge 
of disease mechanisms (Duret, 2009).   
 
Knowledge about variation in the ANXA2 gene is limited and all variants 
identified in this case-control association study would thus contribute to our 
understanding of the association between specific genetic variants in the 
ANXA2 gene and PE. 
 
4.1.1 ANXA2 5’UTR and 3’UTR   
 
The 5‟UTR and 3‟UTR of human genes vary from gene to gene and are 
consequently exceptionally diverse, contributing to the difficulty in analysing 
and characterising these regions.  These untranslated areas are known to 
contain various regulatory elements to which transcription factors would bind 
for functional transcriptional activation.   Mutations in the 5‟UTR and 3‟UTR 
could influence the structure of chromatin, directly affecting access of 
transcription factors and RNA polymerase II to chromatin and therefore the 
binding of these factors to DNA.  Mutations in transcription factors and 
transcription factor binding sites have been associated with disease 
(Remmers et al., 2007; Edberg et al., 2008).  It is therefore clear that the 
analysis of the ANXA2 5‟UTR and 3‟UTR would play a critical role in 
determining whether variants in these regions could be associated with severe 
early onset PE in the South African population.   
  
 i) HWE Analysis and Significant Associations 
 
The deviation from HWE at SNP c.-92 A>T in the total maternal pre-eclamptic 
patient cohort could be an indication of a genuine genetic association between 
this locus and the pathophysiology of PE (Schaid and Jacobsen, 1999).  In 
this study, the deviation from HWE could therefore be a result of the genetic 
mechanism of the disease causing an association of the minor allele T with 
PE, because of a rare dominant disease susceptibility allele.  The significant 
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associations identified in the total maternal (p=0.039) and Black fetal 
(p=0.019) patient cohorts between the locus c.-92 A>T and PE corroborates 
the deviation from HWE in the total maternal patient cohort, since an 
association between this SNP and the underlying etiology of PE could mean 
that the minor allele T play a role as a susceptibility factor to severe early 
onset PE.   
   
A significant departure from HWE at locus c.-31 T>C in the maternal and fetal 
patient and control study cohorts was identified in this study.  Possible 
reasons for deviation from HWE could be because of assertive mating, 
inbreeding, selection, random genetic drift, gene flow, population stratification, 
mutations, DNA quantity or quality and genotyping errors (Hartl et al., 1997).  
In this study, low DNA quantity or quality due to degradation were considered 
a possible reason.  This could thus explain the lack of heterozygous 
individuals observed in this study population as it could be the result of allelic 
dropout or false alleles (Taberlet et al., 1996).  A more recent study by 
Pompanon et al. (2005) emphasized the reality of human handling and 
experimental errors and the consequences of these genotyping errors on 
results.  In this study however, experimental procedures, genotyping and 
statistical analysis were performed with immense care and precision to ensure 
accurate and reliable results.        
 
Unfortunately no allele or genotype frequencies for the SNP c.-31 T>C are 
electronically available for the African-American and Sub-Saharan African 
populations.  A previous study by Hassan et al. (2003) demonstrated a 
significant difference in genotype and allele distributions in selected cytokines 
between African-American and Caucasian populations.  According to 
genotype frequencies retrieved from the Entrez SNP database, 
(http://www.ncbi.nlm.nih.gov/SNP) the minor allele C of SNP c.-31 T>C was 
present in the Caucasian population at a frequency of 92.0%, compared to the 
frequency of 62.3% observed in the South African population.  In accordance 
with the study by Hassan et al. (2003) this study substantiates that differences 
67 
 
in allele and genotype frequencies are found between various ethnic 
population groups.  
 
The significant associations observed in both the maternal and fetal patient 
study cohorts between the SNP c.-31 T>C and PE were not taken into 
account, due to the significant departure from the HWE in both patient and 
control study cohorts.  Other than SNPs c.-92 A>T and c.-31 T>C, none of the 
other variants identified in the proximal promoter region or the 3‟UTR of the 
ANXA2 gene in the patient and the control study cohorts, deviated from the 
HWE or demonstrated a significant deviation in the allele and genotype 
frequencies between the control and maternal and fetal PE patient study 
cohorts.   
 
 ii) In silico Analysis 
 
Transcription factors play a critical role in the regulation of transcription from 
DNA to RNA through RNA polymerase II.  In a study by Iwakuma et al. (2005) 
dysfunctional transcriptional regulation by the disruption of transcription 
factors as a result of mutations in the DNA binding domain of p53 was 
implicated in severe disease phenotypes such as cancer.  Recently, the focus 
on promoter analysis and characterisation has expanded tremendously, as 
knowledge regarding the transcriptional regulation of genes has been limited.  
Information on how this process could be affected by the disruption or 
activation of transcription factors may explain the association of variants        
c.-92 A>T and c.-31 T>C with the study cohorts and PE.   
 
Promoter analysis in this study revealed conflicting results, with only TESS 
and AliBaba2 corresponding in the prediction that the SNP c.-191 G>C would 
create a Sp1 site.  Sp1 (specificity protein 1) is known to function either as an 
activator or as a basal promoter element (Bouwman and Philipsen, 2002;                 
Nichols et al., 2003), depending on the nature of the promoter, which binds 
and acts through CG boxes in order to regulate transcription in multiple genes 
(Suske, 1999).  The ANXA2 promoter region is particularly CG-rich and the 
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creation of a Sp1 site in the promoter region could therefore affect the 
transcriptional activity of the ANXA2 gene. However, no association was 
identified between this SNP and PE and the predicted effect would therefore 
not be strong.    
 
Two other transcription factors that were frequently predicted to be abolished 
in the presence of the variants located within the ANXA2 5‟UTR were NF-1 
and BRCA1.  Alibaba2 predicted that NF-1 would be abolished in the 
presence of the variants c.191 G>C and c.-189_-188insGCCGG and JASPAR 
CORE predicted that BRCA1 would be abolished in the presence of the 
variants c.-135 C>G and c.-31 T>C.   
 
NF-1 (nuclear factor 1) is a constitutively expressed transcription factor that 
can either be activated or repressed during transcription.  A recent study by 
Zhao and Ennion (2006) confirmed NF-1 functioning as a repressor, by 
demonstrating that mutations in NF-1 resulted in a reduced P2X1 promoter 
activity.  BRCA1 (breast cancer susceptibility gene 1) was an interesting 
transcription factor to investigate, since it has been implicated in chromatin 
folding and is known for its role in DNA-repair, rather than the transcriptional 
process itself (Ye et al., 2001).  The mechanism by which BRCA1 functions is 
different to that of Sp1, since it does not bind to DNA sequences specifically, 
but associates with DNA independently and has a preference for abnormal 
DNA structures (Paull et al., 2001).  
 
Variant alleles of the SNPs identified in the ANXA2 proximal promoter of the 
ANXA2 gene could affect transcriptional regulation by creating or disrupting 
putative transcription factor binding sites.  In the case of the creation of a 
putative site (eg, in this study the creation of a putative Sp1 site caused by the 
SNP c.-191 G>C), the binding of a corresponding transcription factor could 
effect transcriptional regulation by acting either as an activator or a repressor.  
The abolishment of a transcription factor binding site (eg, in this study, the 
abolishment of the putative BRCA1 caused by variants c.-191 G>C and        
c.-189_-188insGCCGG and NF-1 sites caused by the SNPs c.-135 C>G and 
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c.-31 T>C) would in theory cause that the corresponding transcription factor 
cannot bind and „normal‟ transcriptional regulation may be disrupted.   
 
These predictions suggest that the above-mentioned SNPs could affect the 
transcriptional activity of the ANXA2 gene and in doing so, affect the up- and 
down regulation of annexin II expression.  A variation in the levels of the 
annexin II protein could contribute to the binding of this protein to PP13, and 
consequently affect the transport of PP13 across the maternal-fetal interface.  
Although these predictions give an indication of the putative effect of the 
variants in the ANXA2 5‟UTR and the possible role it could play in the 
progression of this disease, it is recommended that the effect of gene 
regulation should be validated experimentally.   
 
The SNP c.*1057 A<G, located within the 3‟UTR, was identified in one patient, 
and only in a heterozygous state.  Although this SNP was present at an 
extremely low frequency, variants in the 3‟UTR have previously shown to 
influence mRNA stability (Wang et al., 2005a; Orsi, 2007).  Unlike the case for 
the 5‟UTR, no in silico tools are available to predict the putative effect of the 
c.*1057 A>G SNP on the regulation of translation initiation in the ANXA2 
gene.  Since the 3‟UTR is proposed to enhance the translational efficiency of 
mRNA and play a role in the transport of mRNA from the nucleus to the 
cytoplasm (Sachs et al., 1997), variants in the ANXA2 3‟UTR could affect 
annexin II protein formation.  The predicted functional effect of SNP c.*1057 
A>G on annexin II however needs to be validated experimentally.   
 
4.1.2 Coding Regions 
 
A study by Cargill et al. (1999) indicated that only a few SNPs in the coding 
sequences of genes would be present at a high frequency.  However, SNPs in 
regulatory and coding regions of the genes, especially those responsible for 
amino acid substitutions are thought to have the largest impact on protein 
function (Collins et al., 1997).  The identification of variants in the coding 
region of the ANXA2 gene is therefore crucial, because it could have a 
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functional impact on the annexin II protein and thereby contribute to the 
phenotype of the disease.  
 
 i) HWE Analysis and Significant Associations 
 
A statistically significant association between the coding SNP                       
c.222 C>T; p.Ala74Ala located within exon 4, and severe early onset PE was 
identified in the total maternal (p=0.008), Mixed Ancestry maternal (p=0.035) 
and total fetal (p=0.019) patient study cohorts.  The minor allele T was present 
in three of the 54 control individuals, but was completely absent from all 
maternal and fetal cohorts, implying a possible protective effect.  It could be 
hypothesised that the T allele contributes to a reduced risk for the 
development of severe early onset PE in this specific study population.  PE, 
however, is a complex disease and numerous variants in multiple genes 
would play a role in the pathology of PE.   Although single variants have 
previously been associated with disease, the frequency of these alleles 
remain low and the association demonstrated between this SNP and PE 
needs to be confirmed in other studies.   
 
 ii) In silico Analysis 
 
Although a significant association was identified between variant c.222 C>T; 
p.Ala74Ala and PE, in silico analysis revealed no predicted functional or 
pathological effect of this variant on the annexin II protein.  In silico analysis, 
however, revealed interesting results for variants that showed no significant 
association with PE.  
 
As reported in section 3.4.3, the exonic SNP c.934 G>A; p.Gly312Ser was 
predicted to affect protein function by two independent software programs 
SIFT and PMUT.  These programs predicted that the Glycine to Serine amino 
acid substitutions at residue 312 in the annexin II protein could have a 
pathological affect on the function of annexin II.  The SNP could consequently 
affect the structure and function of the ANXA2 gene in cellular, molecular and 
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physiological processes.  Although results obtained by in silico analysis are 
only an indication of the effect of the variants involved, several studies have 
confirmed results obtained by these predictive programs (Volinia et al., 2005; 
Skalsky et al., 2007).   
 
Exonic splicing elements (ESE) are motifs that play an imperative role in 
recognising alternative splice sites via serine arginine (SR) proteins. These 
elements occur frequently in the human genome and are present in most 
exons (Wu et al., 2005).  The creation of an ESE motif, as predicted by ESE 
Finder in the presence of the variant allele T at SNP c.292 G>T; p.Val98Leu, 
could affect mRNA splicing by inaccurate and ineffective recognition of the 
exon boundaries.   
 
Pre-mRNA splicing has been shown to be influenced by variants such as 
missense, nonsense and silent DNA sequence variants (Pagani and Baralle, 
2004).  These variants could alter the functioning of splicing machinery, 
resulting in exon skipping or the activation of cryptic splice sites.  The 
accuracy and efficiency of splicing are directly affected by these splicing 
abnormalities, resulting in the formation of defective or aberrant mRNA 
isoforms which could be associated with the pathophysiology of PE.  
 
The translation of aberrant mRNA isoforms could affect the final protein 
product, which would subsequently impact the annexin II/PP13 binding.  
Impaired binding could influence the transport of PP13 across the maternal-
fetal interface which would explain reduced PP13 protein levels observed in 
pre-eclamptic pregnancies and contribute to our understanding of this 
complex disease. Functional analyses are thus recommended to validate the 
predictions and effects of the variants identified in the ANXA2 coding region.   
 
 
 
 
72 
 
4.1.3 Intronic Regions 
  
Introns were once considered “junk” DNA, as they are removed from the 
genome and were not considered to play a role in gene expression.  In a 
study by Nott et al. (2003) the significant role of introns in molecular evolution 
and regulation of gene expression was emphasized.  This study employed a 
luciferase-based reporter system in which contructs containing the TPI intron 
6 in two different locations within the open reading frame of the Renilla 
luciferase indicated that intron 6 significantly improved mRNA accumulation.  
Another study identified a significant association between multiple intronic 
SNPs in intron 7 of the TSH Receptor (TSHR) gene and Graves‟ disease in a 
Japanese cohort (Hiratani et al., 2005).  Previously SNPs located within 
intronic regions of the ANXA2 gene were associated with sickle cell 
osteonecrosis (Baldwin et al., 2005). These studies have proven the 
relevance of investigating intronic SNPs in various candidate genes 
associated with disease phenotypes and pathology.  
 
 i) HWE Analysis and Significant Associations 
 
The deviation from HWE at locus c.-12+75 C>A in the Black maternal patient 
cohort (0.0426) and c.244-76 C>G in the Mixed Ancestry fetal patient cohort 
(0.0000) could be explained by the population being stratified into smaller 
subgroups.  Analysis of the subgroups allowed studying of genotype and 
allelic distribution between the different ethnic populations, which could 
contribute to our understanding of associations of variants present in specific 
populations with PE.  The significantly reduced sample size however, affected 
the statistical power and could be the reason for deviation from HWE in some 
of the smaller subgroups.  It is therefore recommended that genotyping of 
these SNPs should be replicated in larger Mixed Ancestry and Black 
populations.  
 
A significant difference in the allele frequency between the Black maternal 
patient subgroup and control group (p=0.018) was identified at intronic SNP 
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c.244-76 C>G, since the minor allele G was present at a higher frequency 
(11.5%) in the patient cohort, compared to the control cohort (2.9%).  
Although this SNP was present in the Black population at a low frequency this 
SNP could represent a possible susceptibility to PE in the South African Black 
population.   
 
The minor allele A of SNP c.449-17 G>A occurred more frequently in the 
control cohort (17.9%), compared to the Black fetal patient cohort (3.0%) and 
the Black maternal patient cohort (3.2%), suggesting a possible protective 
effect.  This association suggests that the minor allele A could confer 
reduction in the risk of developing PE or play a protective role in the 
development of PE, which if investigated in different larger populations, could 
contribute to our knowledge of the underlying mechanism of PE.  
 
The intronic SNP, c.589-5 C>T located within intron 8 revealed a significant 
difference in allele frequencies between all fetal patient and control cohorts 
(p=0.041).  The complete absence of this SNP in the control cohort, compared 
to its frequency in the fetal patient cohort (3.9%), suggests a possible 
susceptibility to PE.  Again the minor allele T was present at a very low 
frequency and along with the marginal association with PE it is recommended 
that the allele frequency of this SNP be determined in a larger population 
before a conclusion can be drawn about the role this SNP would play as a 
susceptibility allele to PE.   
 
 ii) In silico Analysis 
 
In silico analysis of the SNP c.589-5 C>T, using the internet based programs 
Alternative Splice Site Predictor (ASSP) and NetGene2 as described in 
section 3.5.2, predicted no effect on alternative splicing.  Predictions made by 
both these programs were contradictory, which suggests that programs for in 
silico analysis should be employed only to give an indication of the possible 
effects of variants on alternative splicing.  Functional analysis using 
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approaches such as minigene assays are thus recommended to validate the 
predictions and effects of these SNPs (Baralle et al., 2003).  
  
4.1.4 Technique Evaluation 
 
In an attempt to eliminate genotyping errors as the reason for departure from 
HWE, HEX-SSCP analysis was employed to confirm genotypes for the SNP 
c.-31 T>C observed by Multiphor SSCP/HD analysis.   The results indicated in 
section 3.2.1 show that Multiphor SSCP/HD analysis was more sensitive than 
HEX-SSCP analysis, since conformational variants which were identified on 
the Multiphor gels and confirmed with bi-directional DNA sequencing, were 
not detected with the HEX-SSCP technique.  Although Multiphor SSCP/HD 
analysis proved to be more sensitive, RFLP analysis using mutagenic primers 
and bi-directional DNA sequencing are recommended in order to ensure 
accurate and reliable genotype and allele frequencies for SNP c.-31 T>C in 
this study cohort.   
 
Multiphor SSCP/HD analysis was used to screen most of the ANXA2 gene, 
the only exception being the amplicon representing exon 10.  Although 
Multiphor SSCP/HD analysis proved to be more sensitive than HEX-SSCP 
analysis, genotypes could not be discerned with confidence and the SNP 
identified by DNA sequencing was genotyped by RFLP analysis.  It is 
therefore a possibility that other variants present in samples that were not 
subjected to DNA sequencing of this amplicon, were overlooked.  In future it is 
thus recommended that this amplicon is screened for DNA variations using an 
alternative method of mutation detection.    
 
In this study, conformational variants could be identified on the SSCP and HD 
components of Multiphor SSCP/HD gels, but the presence of more than one 
variant in an amplicon complicated the observation and clear visualisation of 
the different conformations on the gels.  Consequently, conformations often 
needed to be confirmed with bi-directional DNA sequencing and RFLP 
analysis.  Apart from direct bi-directional DNA sequencing, other screening 
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methods such as denaturing high-performance liquid chromatography 
(dHPLC) and high resolution melt (HRM) analysis are therefore recommended 
for future use (Fassano et al., 2005; Takano et al., 2008).  These high-
throughput techniques are ideal for screening large genes for novel DNA 
mutations (eg, SNPs, small deletions and insertions) with high sensitivity and 
efficiency.  
 
4.1.5 Haplotype Analysis 
 
Haplotype analysis, using the four gamete rule, revealed a significant level of 
LD between SNPs c.-11-43 G>A and c.-11-13 A>T in the Mixed Ancestry and 
Black maternal study cohorts (D‟ = 1.0, LOD > 43.56, r2 = 1.0) and the Mixed 
Ancestry and Black fetal study cohorts (D‟= 1.0, LOD > 40.19, r2=1.0).   These 
SNPs are located a mere 30 bp from each other within intron 1, which might 
explain the reason for the strong LD between them.  The SNPs represent 
tagSNPs that could be used to genotype one SNP with the purpose of 
predicting the genotype of another SNP (or SNPs) in LD, allowing for effective 
high throughput genotyping (Sobrino et al., 2005).  In future instead of two 
restriction enzyme digests, as was performed in this study, genotypes for one 
SNP could thus be deduced from genotyping the other SNP by a restriction 
enzyme digest.   
 
Genotype frequencies at these loci (determined in these two South African 
population groups) were compared to genotype frequencies reported in 
Nigerian (YRI) family groups (HapMap).  No LD could be demonstrated 
between SNPs c.-11-43 G>A and c.-11-13 A>T in the Nigerian population 
(D‟=0.773, LOD=2.78, r2=0.36).  Although genotype and allele frequencies in 
different African populations are expected to be very similar, differences in 
populations of different geographical and ethnical heritage occur quite 
frequently as a result of the genetic diversity between African populations 
(Chakravarti, 2001).  
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Recurrent pregnancy loss (RPL) has previously been associated with 
haplotype M2, which comptrises of four SNPs (-19G/A, 1A/C, 27T/C, 76G/A) 
in the 5‟UTR of the ANXA5 gene (Bogdanova et al., 2007).  Recently, a study 
by Tiscia et al. (2009) confirmed the association of haplotype M2 with RPL, 
but furthermore, demonstrated that haplotype M2 is associated with 
gestational hypertension and PE.  None of the other variants identified in this 
study were found to be in significant LD with each other.  It is however 
possible that several of these SNPs may be in LD with variants in other 
genomic regions that were not screened in this study.   
 
4.1.6 Low Frequency SNPs 
 
The variants identified in this study are present at a very low frequency in both 
patient and control study cohorts.  Possible reasons for the absence of 
homozygous genotypes (for the variant allele) could be because the minor 
alleles of these variants are present at such a low frequency, that it could not 
be detected by genotyping 120 pre-eclamptic maternal and 94 fetal individuals 
(Glatt et al., 2001).  Sixteen of the 25 variants identified are novel variants that 
have not previously been characterized in the South African Black and Mixed 
Ancestry populations.  Consequently, it could be hypothesized that these 
variants do not occur in other specific ethnic groups or that different 
susceptibility loci could be implicated in the risk of developing PE in different 
population groups.  
 
4.1.7 Comparison of the Genotype and Allele Frequencies in Different 
 Ethnic Populations 
 
Population frequencies can be influenced by various factors.  There are 
significant differences in allelic frequencies of variants in numerous genes in 
different cultural and ethnic groups (Kreek et al., 2005).  It is therefore 
important to consider ethnicity.  The allelic frequencies obtained in this study 
population can therefore be compared to that of similar studies previously 
performed in different populations and ethnic groups.   
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The minor allele for the previously documented SNP c.-31 T>C             
(dbSNP: rs12904657) located within the 5‟UTR of the ANXA2 gene was 
present in the total maternal patient population at a frequency of 62.1% which 
correlates with the frequency observed in the Caucasian population (73.0%).  
Unfortunately no frequencies in the Asian and Sub-Saharan African 
populations were available and it could thus not be used to determine how 
similar these frequencies are.  
 
As presented in Appendix H, Table 1, the genotype and allele frequencies for 
the three SNPs c.975 C>T; p.Gly325Gly, c.-11-43 G>A and c.48+67 C>T 
were present at a lower frequency in this study than in the European, Asian 
and Sub-Saharan African populations and SNP c.-11-13 A>T occurred at a 
higher frequency in this population compared to the other three populations.  
SNPs c.449-17 G>A and c.683-56 G>A were more prevalent in this study 
compared to the Sub-Saharan African population, but was present less often 
when compared to the European and Asian populations.  Although a 
difference in the frequencies could be observed between the different 
populations, the frequencies of four of these SNPs (c.-11-13 G>A,       
c.48+67 C>T, c.449-17 G>A, c.683-56 G>A) in the two South African 
populations used in this study, was very similar to the frequencies observed in 
the Sub-Saharan populations.  The correlation between these frequencies 
was expected, since the study participants represented Mixed Ancestry and 
Black women.   
 
Genotype and allele frequencies for only one previously documented exonic 
SNP c.975 C>T; p.Gly325Gly, also identified in this study, were available on 
the Entrez SNP database, (http://www.ncbi.nlm.nih.gov/SNP/).  The frequency 
of the variant allele T was found to be 56.7% in the European, 50.0% in the 
Asian and 44.2% in the Sub-Saharan African populations (Appendix H, Table 
1).  Interestingly, in the current study, the T allele was present in the total 
maternal patient and total control cohorts at a frequency of 0.8% and 0.6%, 
respectively.  The frequency of the SNP c.975 C>T; p.Gly325Gly observed in 
the South African population groups used in this study was thus very low 
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compared to other populations.  The variant allele was present in the Mixed 
Ancestry patient population at a frequency of 1.4% and 1.9% in the control 
cohort, but was completely absent from the Black population.  A recent study 
by Coop et al. (2009) suggested that this would most likely not be as a result 
of selection based on geographical area, but that migration, population history 
and drift could be the cause of high allelic differences between populations.  
 
4.2 Limitations of this Study 
 
i) Sample Size 
 
The relatively small population size of 120 maternal and 94 fetal patient 
individuals along with 54 control individuals, could explain the reason for the 
lack of homozygosity and the low frequencies of heterozygotes for a number 
of SNPs identified in this study.  This limits detection of possible association 
between these polymorphisms and PE. The cohort size could therefore be 
increased in an attempt to increase the genotype and allele frequency.   
 
Different population sizes were used in similar case-control association 
studies investigating candidate genes involved in PE.  A cohort of 89 pre-
eclamptic maternal patients and 349 control women was used in a study by 
Yu et al. (2006) that demonstrated an association between the Asp289Glu 
variant in the eNOS gene and PE, whereas a study by Goddard et al. (2007) 
employed the MassARRAYTM system to genotype 775 SNPs in 190 candidate 
genes in a population comprising 394 pre-eclamptic maternal patients and 
324 control women.   
 
Although our cohort was not as large as those previously documented, the 
size of this population is sufficient to detect variants that are present at a high 
frequency.  The identification of variants that occur at a lower frequency within 
the ANXA2 gene, along with the identification of statistical significant 
associations between these variants and PE would require replication in an 
extended cohort. 
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The Mixed Ancestry maternal patient population (n=71) was considered as the 
focus group in this study and the Black patients (n=49) were included to 
increase the cohort.  The control study cohort however consisted of only 
Mixed Ancestry individuals and it is therefore highly recommended that in 
future a control study cohort of ethnically matched, healthy pregnant women 
for the South African Black population is included to ensure more accurate 
comparisons in genotype and allele frequencies between patient and control 
groups.  
 
ii) Multiple Testing 
 
A further limitation of this study is the need for correction for multiple testing, 
since 25 markers were identified within the ANXA2 gene in these two South 
African populations (Mixed Ancestry and Black).  Analysing the data obtained 
in this study, (involving multiple comparisons) could affect the rejection of the 
H0 hypothesis, along with confidence intervals.  Repeated use of statistical 
tests is often responsible for an increased rate of type I errors.  The false 
positive rate associated with multiple tests could be controlled by several tests 
and techniques.  It is therefore recommended that multiple testing should be 
performed by employing Bonferroni corrections such as in a study by Unoki‟s 
et al. (2000), where statistical analysis of 33 SNPs were subjected to 
Bonferroni‟s corrections to ensure the correct conclusions on rejecting the H0.  
In certain cases, where this technique is too conservative, the Post-hoc 
testing of ANOVA could be employed.       
 
iii) Complexity of the Disease 
 
PE is a multifaceted disease and currently no cure is available.   Screening a 
candidate gene such as ANXA2 contributes to insight and knowledge about 
the pathology of the disease.  PE however, remains a complex disease and 
cannot be explained by variation(s) in a single gene.  Multiple candidate 
genes should therefore be studied simultaneously to identify a possible 
association between genetic variants and the pathogenesis of PE.  Applying a 
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technique that would enable high throughput genotyping could accelerate 
analysis of variants in numerous genes involved in healthy and complicated 
pregnancy.  Multi-disciplinary approaches to analysing and investigating 
several factors involved in the disease process would broaden the spectrum 
of possible causes.  The results of such a study could be useful in a clinical 
setting, as they may provide valuable insight into the mechanisms underlying 
PE.  
 
4.3 Future Research and Conclusions 
 
The research hypothesis for this study was to determine whether variants in 
the ANXA2 gene confer susceptibility or protection in PE, and in doing so 
expand our knowledge and understanding of the pathogenesis of this complex 
disease.   
 
The original aims for this study as stated in section 1.12 were successfully 
achieved; 
 
o the ANXA2 gene and 600 bp of the proximal promoter area were 
successfully characterised, 
o sixteen of the 25 variants identified in the ANXA2 gene in the South 
African population, were novel variants, 
o the genotype and allele frequencies for these variants were identified in 
the Mixed Ancestry and South African Black study cohorts. 
o significant association was identified between one exonic SNP        
(c.222 C>T; p.Ala74Ala), three intronic SNPs (c.244-76 C>G, c.449-17 
G>A, c.589-5 C>T) and one SNP in the ANXA2 5‟UTR (c.-92 A>T) and 
PE,  
o the SNP c.-92 A>T located within the ANXA2 5‟UTR demonstrated 
significant association with PE in the total maternal patient cohort 
(p=0.039) and Black fetal patient cohort (p=0.019),   
o the exonic SNP (c.222 C>T; p.Ala74Ala) demonstrated a significant 
association with PE in the total maternal patient cohort (p=0.008), the 
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Mixed Ancestry maternal patient cohort (p=0.035)and total fetal patient 
cohort (p=0.019), 
o significant association was identified between the following intronic 
SNPs and PE: SNP c.244-76 C>G demonstrated a significant 
association in the Black maternal patient cohort (p=0.018), SNP           
c.449-17 G>A demonstrated a significant association in the Black 
maternal patient cohort (p=0.032) and Black fetal patient cohort 
(p=0.030) and SNP c.589-5 C>T demonstrated a significant association 
in all the fetal cohorts (p=0.041),   
o significant LD (D‟ = 1.0, LOD > 40.19, r2 = 1.0) was demonstrated 
between two intronic SNPs  (c.1-54 G>A and c.1-24 A>T ) in the total   
maternal and fetal patient groups and subgroups, 
o in silico analysis identified three SNPs, c.-191 G>C in the 5‟UTR,   
c.934 G>A; p.Gly312Ser in exon 12 and c.292 G>T; p.Val98Leu in 
exon 5 that warrants experimental validation of the role these SNPs 
could play in the structure and function of annexin II in cellular and 
molecular processes.   
o the three SNPs c.975 C>T; p.Gly325Gly, c.-11-43 G>A and         
c.48+67 C>T were present at a lower frequency in this study than in the 
European, Asian and Sub-Saharan African populations and SNP         
c.-11-13 A>T occurred at a higher frequency in this population 
compared to the other three populations.   
o SNPs c.449-17 G>A and c.683-56 G>A were more prevalent in this 
study compared to the Sub-Saharan African population, but were less 
common compared to the European and Asian populations.   
 
Although 25 variants were identified in the ANXA2 gene, association could 
only be demonstrated at only five loci.  The frequencies of these SNPs in the 
South African pre-eclamptic population were extremely low and although they 
would most likely not have a functional role in the pathology of PE, these 
SNPs could serve as susceptibility loci.  Identifying SNPs associated with PE, 
remains important since it enhances the ability for early identification of 
individuals at risk of severe ealy onset PE.   
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This is the first study, to our knowledge, to screen the ANXA2 gene in a pre-
eclamptic population and by doing this a general view of the ANXA2 gene on 
the molecular level was obtained. The findings in this study therefore 
contributed tremendously to our knowledge and understanding of the role 
ANXA2 plays in healthy and pre-eclamptic pregnancies and set a good 
foundation for future studies.  
 
Suggestions for future research would include the following:  
 
i) In addition to screening the ANXA2 gene in a larger cohort, this study 
should be replicated in other population groups to allow for comparison 
of genotype and allele frequencies. 
  
ii) Conventional microarray technology would facilitate the study of genes 
that are differentially expressed in PE patients compared to healthy 
pregnant women.  In a study by Reimer et al. (2002) placental tissue of 
PE patients was analysed for differential expression in multiple genes 
using DNA microarray analysis, revealing that obesity related genes, 
such as leptin, were up-regulated during PE.  Although this approach 
has been employed before, LGALS13 and ANXA2 genes were not 
included in those studies.  A similar study, including these specific 
genes, could therefore contribute to our understanding of their possible 
effect and function in the pathology of PE. 
  
iii) The SNP c.-191 G>C identified in the ANXA2 5‟UTR, should be further 
analysed in an attempt to determine its functional effect on the 
regulation of the ANXA2 gene.  Chromatin immunoprecipitation assays 
(ChiP) (Wells and Farnham, 2002) and electromobility shift assays 
(EMSA) (Prusty and Das, 2005) could be used to analyse and 
characterise the putative transcription factor binding sites predicted to 
be affected in the presence of the c.-191 G>C SNP.   
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iv) Functional analysis, employing minigene assays of SNPs c.934 G>A; 
p.Gly312Ser and c.292 G>T; p.Val98Leu should be performed to 
determine their possible functional effect on the annexin II protein 
(Baralle et al., 2003).  Structural modelling of annexin II and PP13 with 
and without these variants by X-ray crystallography could contribute to 
the understanding of how protein binding between annexin II and PP13 
is affected by functional variants.     
 
v) Annexin II levels should be measured in the sera of PE maternal 
patients and compared to levels in healthy pregnant mothers in the 
South African population.  In Europe, PP13 levels are currently being 
measured using ELISA and is performed during the first trimester of 
pregnancy (Diagnostic Technologies Limited, Israel). This allows early 
prediction and identification of women who will subsequently develop 
PE, allowing early intervention and prophylaxis.  Although this is 
currently not financially viable in South Africa, comparing measured 
annexin II levels with genotypes of SNPs identified in the ANXA2 gene 
in pre-eclamptic patients and healthy pregnancies could ellucidate the 
association of variation in the ANXA2 gene and PE.  Significant 
differences in annexin II levels in PE patient and control individuals 
would contribute to our knowledge about the function of the ANXA2 
gene.  Annexin II levels should furthermore be measured concurrently 
with PP13 levels and analysed in combination with genetic screening 
results of the ANXA2 and LGALS13 genes to expand the accuracy and 
efficiency of genotyping tests.   
 
 
Healthy pregnancy involves a complex interplay of various bio-molecules to 
ensure normal development.  The etiology underlying PE is still unknown, 
emphasizing the importance of identifying genes predisposing to this life 
threatening disease.  Screening candidate genes, such as ANXA2, in 
combination with functional and biochemical analyses, could enhance our 
understanding of the underlying pathology of PE and contribute to the 
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development of an early biomarker.  Early detection of PE would facilitate 
early intervention, hospital care and monitoring of pregnancies which would 
ultimately result in better pregnancy outcome and decreased mortality and 
morbidity rates.      
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6 APPENDICES 
 
Appendix A: Informed Consent Forms 
 
FACULTY OF HEALTH SCIENCES 
STELLENBOSCH UNIVERSITY 
 
INFORMATION AND INFORMED CONSENT 
DOCUMENT FOR DNA ANALYSIS AND 
STORAGE 
 
TITLE OF THE RESEARCH PROJECT: Profiling placental protein 13 / 
galectin-13 in pre-eclampsia. 
REFERENCE NUMBER: …………………………………..………..……………. 
PRINCIPAL INVESTIGATOR: Drs R Hillermann & GS Gebhardt  
Address: Departments of Obstetrics and Gynaecology and Genetics, 
University of Stellenbosch, Tygerberg and Paarl Hospital 
 
DECLARATION BY OR ON BEHALF OF PARTICIPANT: 
I, THE UNDERSIGNED, 
……………………………..…………………………………….. (name) 
[ID No: ……….……………] of …………………….…………………………. 
……….…………………...……………………………………………………………
…… (address). 
 
A. HEREBY CONFIRM AS FOLLOWS: 
1. I was invited to participate in the above-mentioned research project 
of the Departments of Obstetrics and Gynaecology and Genetics, 
Faculty of Health Sciences, University of Stellenbosch. 
2. The following aspects have been explained to me: 
Aim: Pre-eclampsia (high blood pressure in pregnancy) is a severe 
complication of pregnancy and it affects about 5% of all 
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pregnancies. Currently there is no way to predict who will be 
affected. We are investigating a protein normally secreted by 
the placenta (the afterbirth) as it seems that this protein may 
predict the development of later problems.    
2.1  Procedures:    I will be requested to provide information 
about my medical history.    Blood (10ml, about 2 teaspoonfuls) 
will be collected from me at delivery of my baby together with the 
routine blood samples taken at birth. In addition 6 small biopsies 
(pea-size) will be taken from the afterbirth (the placenta) after 
delivery and before the placenta is routinely destroyed.    
2.3 Genetic considerations 
 The DNA may be stored for several years until the 
technology for meaningful analysis becomes available;  
 The clinically relevant results of the (possible) analyses 
carried out on this material in the current study can be 
made known to me at my request and in accordance 
with the relevant protocol, if and when it becomes 
available.    In addition, I authorise(s) the investigator(s) 
to make the information available to 
……………….………….…………(doctor’s name), the 
doctor involved in my care, as well as to the following 
family members ……………………………..………… 
.………………………………………..………………………
…… (names); 
 The DNA will be maintained indefinitely, unless I request 
to have it and/*or the stored clinical data destroyed by 
contacting the investigator conducting the present study, 
dr GS Gebhardt at 938 9131 or the Chairperson of the 
Research Subcommittee C/Ethics Committee at 
9389111 if the former cannot be located; 
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 The analyses in the current study are specific to the 
condition or disease mentioned above and cannot 
determine the entire genetic make-up of an individual; 
 Genetic analyses may not be successful in revealing 
additional information regarding some families or some 
family members; 
 Even under the best conditions, current technology of 
this type is not perfect and could lead to unreliable 
results. 
2.4 Confidentiality:  My identity will be kept confidential 
throughout.     Information will not be associated with my 
name.  The research staff will use only a coded number, 
access will be limited to authorized scientists and any 
scientific publications, lectures or reports resulting from the 
study will not identify me by name.  
2.5 Voluntary participation: Participation is voluntary and I may 
decline participation, or withdraw from the study at any time 
without any loss of benefits to which I am otherwise entitled.    
Future management at this or any other institution will not be 
compromised by refusal or withdrawal. 
2.6 Risks:   There are no more than minimal medical or 
psychological risks associated with this study: 
 I may feel some pain associated with having blood 
withdrawn from a vein and may experience discomfort, 
bruising and/or slight bleeding at the site; 
 Biopsies of the placenta is not painful as it is taken after 
delivery before routine destruction of the placenta 
 As some insurance companies may mistakenly assume 
that my‟ participation is an indication of a higher risk of a 
genetic disease which could hurt my access to health or 
other insurance, no information about me or my family 
will be shared with such companies as this investigation 
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cannot be regarded as formal genetic testing for the 
presence or absence of certain genes. 
 
2.7 Benefits:   
 Although there may not be any direct benefits to me by 
participating at this stage, family members and future 
generations may benefit if the researchers succeed in 
scientifically delineating certain disorders further.   
Thereby the rational approach to the clinical diagnosis 
and therapy of its manifestations may be facilitated.  The 
identification and location of the genes involved in such 
disorders, could in the end lead to the development of 
methods for prevention and to forms of new treatment 
aimed at curing or alleviating these conditions; 
 In the unlikely event that the research may lead to the 
development of commercial applications, I or my heirs 
will not receive any compensation, but profits will be 
reinvested into supporting the cause of further research 
which may bring benefits to my family and to the 
community, such as health screening, medical 
treatment, educational promotions, etc; 
2.8 Permission for further studies:   Before my material is used 
in further projects in the future, the written approval of the 
Research Subcommittee C/Ethics Committee, Faculty of 
Health Sciences, will be obtained. 
3. The information conveyed above was explained to me by 
……..……..……………………………………….………………….……
….. (name) in English and I am fluent in this language 
4. I was afforded adequate time to pose any questions and all 
questions were answered to my full satisfaction. 
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5. I was not pressurized to participate. 
6. I will not be paid for participation, but reimbursement of travel costs 
will be considered (if applicable). 
7. I will not incur any additional costs through participation. 
8. I have/*has received a copy of this document for my records. 
9. The Research Subcommittee C/Ethics Committee, Faculty of Health 
Sciences, Stellenbosch University, has approved recruitment and 
participation of individuals in this study on the basis of: 
 Guidelines on Ethics for Medical Research of the SA Medical 
Research Council; 
 Declaration of Helsinki; 
 International Guidelines : Council for International 
Organisations of Medical Sciences (CIOMS); 
 Applicable RSA legislation. 
 
 
 
 
 
I. I HEREBY CONSENT VOLUNTARILY TO PARTICIPATE/*ALLOW 
THE POTENTIAL PARTICIPANT TO PARTICIPATE IN THIS STUDY: 
 Signed/*Confirmed at ………..……..…………… on………………...20…… 
                                           (place                                          (date) 
 …………………………………………………………………………………… 
Signature or right thumb print of               Signature of witness 
participant/*representative of participant                                 
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DECLARATION BY OR ON BEHALF OF INVESTIGATOR(S): 
I, ……………………………………………………………………………..…(name) 
declare that 
 I explained the information in this document to 
……………………………………. (name of the patient/*participant) and/or 
his/her representative …………………….………… (name of the 
representative); 
 she/*he was encouraged and afforded adequate  time to ask me any 
questions; 
 this conversation was conducted in Afrikaans/*English/*Xhosa/*Other 
…………….……………….. and no translator was used/*was translated 
into ……………………………(language) by 
……………….…………...……………..… (name). 
Signed at ……………………….………….……….  on …….………….20…. 
                                     (place)                     (date) 
………………………………….…………………… …………………………… 
Signature of investigator/representative of investigator  Signature of witness 
………………………………………………… …………………………… 
                  Signature of translator              Signature of witness 
 
IMPORTANT MESSAGE TO PARTICIPANT/*REPRESENTATIVE OF 
PARTICIPANT: 
Dear participant/*representative of participant, 
Thank you very much for your participation in this study.  Should, at any time 
during the study, 
 an emergency arise as a result of the research, or 
 you require any further information with regard to the study,  
kindly contact Dr GS Gebhardt at 938 0131, 938 4707 (after hours) or 87 
21 711 (all hours) or come to the labour ward on the second floor, 
Tygerberg Hospital. 
*Delete where not applicable 
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Appendix B: Protocols 
 
1. Multiphor SSCP/HA analysis  
(Modified protocol retrieved from Liechti-Gallati et al., 1999) 
 
Multiphor SSCP/Heteroduplex gel 
 Wash plates 4X with 70% ethanol 
 Add 80 µl plateglue and 8 µl 10% acetic acid on plate without blocks.  Add 
80 µl repelcote onto the plate that contains wells 
 Wipe until resistance is felt and wash a few times with 70% ethanol 
 Wipe spacers with 70% ethanol and place them on the plates 
 Clamp on both short sides and the long area close to blocks (wells).  Place 
upside down on bench 
 Prepare gel mix  
o 15 ml gel mix (Appendix C) 
o 150 ml 10% APS (Appendix C) 
o 15 ml TEMED (Promega, Madison WI, USA) 
 Pour quickly using a syringe 
 Allow to set at room temperature for 30 minutes 
 
Setting up the apparatus (Amersham Pharmacia Biotech, Amsterdam, UK) 
 Separate plates 
 Add dH2O onto surface of Multiphor apparatus  
 Slide plate with gel facing upwards over water 
 Use 2 Whatmann buffer strips per side per 2 hour run soaked in TRIS-
borate buffer (Appendix C) 
 Place strips on both sides of gel close to the wells 
 Wash electrodes of Multiphor gently each time before use 
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PCR products 
 Take 3-5 µl PCR product and 3 - 5 µl SSCP loading dye (Appendix C) 
 Denature at 95ºC for 5 min in PCR thermocycler 
 Place on ice immediately  
 Load 3 µl onto gel and run at optimised temperature (4ºC - 21ºC) for 
optimised duration at 355 V 
 
Visualisation of bands 
 Remove gel from apparatus 
 Rinse 2X in dH2O  
 Incubate for 10 min at room temperature in solution 1 (Silver Nitrate 
solution) (Appendix C) 
 Rinse 2X in dH2O 
 Incubate for 10 min at room temperature in solution 2 (Developing 
Soloution) (Appendix C) 
 Rinse 2X with dH2O 
 Blot dry with paper towel 
 Cover gel with Whatmann filter paper 
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2. Protocol for genomic DNA extraction from whole blood  
(Protocol retrieved from Miller et al., 1988) 
 
Day 1: 
 
 Place ~10 ml blood in a 50 ml Falcon tube 
 Add 30 ml cold Lysis Buffer (Appendix C) 
 Place on ice for 15 min, shaking each 5 min interval 
 Centrifuge @ 1500 rpm for 10 min 
 Pour off supernatant, keeping pellet 
 Add 10 ml PBS (Appendix C) and mix 
 Centrifuge @ 1500rpm for 10 min 
 Pour off supernatant keeping pellet 
 Dissolve Pellet in: 30 ml Cell Lysis Buffer 
30 µl Proteinase K (10 mg/ml) 
300 µl 10% SDS 
 Mix well and incubate overnight in 55 ºC waterbath 
 
Day 2: 
 
 Add 1 ml 6M NaCl and shake for 1 min 
 Centrifuge @ 3500 rpm for 30 min 
 Transfer supernatant to new tube and shake for 15 s 
 Centrifuge @ 2500 rpm for 15 min 
 Transfer supernatant to new tube without foam or pellet 
 Add 2 volumes ice cold 100% ethanol to precipitate DNA 
 Scoop out DNA and place in Eppendorf tube with 500 µl 70% ethanol 
 Centrifuge @ 14 000 rpm for 10 min @ 4ºC  
 Dissolve pellet in 200-800 µl ddH2O/TE buffer depending on pellet size 
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3. Rapid DNA isolation from 300µl whole blood using the Pure Gene® 
DNA isolation Kit (Gentra Systems™, Minneapolis, USA) 
 
Cell Lysis 
 Add 300 µl whole blood to 900 µl RBC Lysis Solution and incubate for 
1 min at room temperature, invert gently 10 times during incubation 
 Centrifuge for 20 s at 13 000 - 16 000 g.   
 Remove supernatant (leave ~10 µl liquid) 
 Vortex pellet to resuspend 
 Add 300 µl Cel Lysis Solution and pipet up and down 
 
Protein Precipitation 
 Add 100 µl Protein Precipitation Solution and vortex at high speed for 
20 s 
 Centrifuge for 1 min at 13 000 - 16 000 g (dark brown pellet forms) 
 
DNA precipitation 
 Transfer supernatant to a clean Eppendorf tube containing 300 µl 
100% isopropanol and mix by inverting samples 50 times. 
 Centrifuge at 13 000 - 16 000 g for 60 s (obtain small white pellet) 
 Pour off supernatant and drain tube on clean absorbent paper 
 Add 300 µl 70% ethanol and invert tube several times to wash pellet 
 Centrifuge at 13 000 - 16 000 g for 60 s 
 Carefully pour of ethanol, invert and drain tube for 30 min on clean 
towel paper 
 
DNA Hydration 
 Add 20 µl DNA Hydration Solution and dissolve for 30 min 
 Store at 4 ºC 
 
 
 
112 
 
Appendix C: Solutions 
 
1. DNA Extraction Method 
 
Extraction Buffers and chemicals used: 
 
 Nuclear Lysis Buffer  
 1,211 g Tris-Cl  0.01 M 
 23,4 g  NaCl  0.4 M 
 0.6 g  EDTA  0.002 M 
  
 pH = 8.2 with 1M NaOH 
 BTV (1 l) with dH2O 
 Storage:  4ºC 
 
 Cell Lysis Buffer 
 8.3 g  NH4Cl  0.155 M 
 1.1 g  KHCO3  0.01 M 
 0.03 g  EDTA  0.0001 M 
 
pH = 7.4 with HCl 
 BTV (1 l) with dH2O 
 Storage:  4ºC 
  
 
 Phosphate Buffered Saline (PBS) 
 2 g  KCl  0.027 M 
 8 g  NaCl  0.137 M 
 1.14 g  Na2HPO4 0.008 M 
 0.2 g  KH2PO4 0.0015 M 
 
 BTV (1 l) with dH2O 
 Storage:  4ºC 
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 10% SDS 
 10g  SDS 
  
BTV (100 ml) with dH2O 
 Storage: Room Temp (Prevent Precipitation) 
 
 Proteinase K 
 10 mg/ml dissolved in dH2O 
  
Storage:  -20ºC  
 
 6 M NaCl  
 175.32 g NaCl 
  
BTV (500 ml) with dH2O 
 
Storage: Room Temp 
 
2. Agarose Gel Electrophoresis 
 10X TBE 
 108 g Trizma Base 
 55 g Boric Acid 
 7.445 g EDTA 
 BTV (1 l) with dH2O.  Dilute 1 in 10 for 1X TBE buffer. 
 
 Cressol 
 Stock Solution: 
 10 mg Cressol 
 Dissolved in 1 ml 
 
 Dilute: 
 200 µl Cressol Stock 
 3.4 g Sucrose 
 9.5 ml dH2O 
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3. Multiphor SSCP/HD Analysis 
 
40% acrylamide-PDA Solution   
396 g Acrylamide  
   4 g Piperazine diacrylamide 
BTV (1 l) with dH2O 
 
0.75 M TRIS-Formate Buffer 
90.8 g Trizma Base 
600 ml dH2O 
pH = 9.0 with formic acid 
BTV (1 l) with dH2O 
 
41% Glycerol 
41 ml Glycerol  
59 ml dH2O 
 
TRIS-Borate Buffer  
125.9 g Trizma Base 
17.3 g Boric acid (H3BO3) 
700 ml dH2O (dissolve) 
pH = 9.0 
50 µl Bromophenol Blue(4% solution) 
BTV (1 l) with dH2O 
 
SSCP loading dye 
95% (47.5ml) Formamide 
100 mM (0.16 g) NaOH 
0.25% (0.125 g) Bromophenol Blue  
0.25% (0.125 g) Xylene Cyanole   
BTV (50 ml) with dH2O 
 
 
 
 
 
 
     10% APS 
     0.15 g APS 
     BTV (1.5 ml) with dH2O 
 
Plateglue 
200 µl 3-(Trimethoxysily) propyl   
         methacrylate 
50 ml 100% Ethanol  
 
Gel Mix (X10) 
53 ml 40% acrylamide-PDA 
85 ml Tris-Formate Buffer 
30 ml 41% Glycerol  
Storage: 4ºC in dark 
 
Silver Staining Solutions 
Solution I 
0.75 g silver nitrate (AgNO3) 
300 ml dH2O 
Storage: in dark for +/- 3 days 
Solution II 
4.5 g Sodium Hydroxide pellets (NaOH)  
300 ml dH2O 
3 ml Formaldehyde solution  
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4. HEX-SSCP Analysis 
 
12% PAA Gel Mix 
12% (w/v) [40% Stock Solution with 1%C (99 Acrylamide : 1 Bisacrylamide)] 
0.1% (w/v) APS 
0.1% (v/v) TEMED 
7.5% (w/v) Urea  
 
Bromophenol blue loading dye 
95% (v/v) formamide 
20 mM EDTA 
0.05% (w/v) xylene cyanol 
0.05% (w/v) bromophenol blue 
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Appendix D: Patient Questionnaires 
 
   GENETIC ASPECTS OF PRE-ECLAMPSIA: 
 NAME: 
 HOSPITAL: 
 BIRTH DATE: 
1. AGE: 
2. RACE: 
3. GRAVIDITY:PARITY:MISCARRIAGES:ECTOPIC 
 
    PREVIOUS PREGNANCIES 
    
4. YEAR:  ............................................................................... 
5. PARTNER: (NO) ............................................................................... 
6. G.A. COMPLICATIONS: .................................................................... 
7. COMPLICATIONS: (LIST) .................................................................... 
8. METHOD DELIVERY: .................................................................... 
9. BIRTHWEIGHT: ............................................................................... 
10. G.A. –DELIVERY: ............................................................................... 
11. OUTCOME: (LIST) ............................................................................... 
12. NICU:YES=1, NO=2 .................................................................... 
13. SMOKE: YES=1, NO=2 .................................................................... 
14. ALKOHOL: YES=1, NO=2 .................................................................... 
 
    CURRENT PREGNANCY 
 
15. VDRL:NEG=0, POS TREATED=1, NOT TREATED=2 
16. BLOOD GROUP: 
17. CERVICAL CYTOLOGY: NORMAL=1, ABNORMAL=2 
18. CERVICAL CULTURES: 
NOT DONE=1, NEG=2, GONO=3, CHLAMYDIA=4, GBS=5, OTHER=6 
19. URINE MCS: NEG=2, ASYMP. BACTERIA TREATED=1, NOT TREATED=2, 
NOT DONE=3, UTI=4 
20. SF GROWTH: <10th=1, NORMAL=2, >90th=3 
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21. PROTEINURIA: (GESTATION) 
22. BP: (ADMISSION) 
23. AMNIOCENTESIS FOR KARYOTYPING: YES=1, NO=2 (GESTATION) 
24. FETAL MOVEMENT:NORMAL=1, DECREASED=2 
25. ULTRASOUND: YES=1, NO=2 
26. DOPPLER:N=1, >95th =2, AEDV=3,REDF=4 
27. G.A. WHEN COMPLICATIONS DEVELOPED: 
28. COMPLICATIONS:……………………………………………………..... 
............................................................................................................ 
29. SMOKE:YES=1, NO=2 
30. ALCOHOL:YES=1, NO=2 
31. MEDICATION AT ANY TIME DURING PREGNANCY: 
FOLATE=1, Fe=2, ASPIRIN=3, 
ANTIHYPERTENSIVES=4,PYRIDOXIN=5,OTHER=6 
32. GESTATION: 
33. BIRTH WEIGHT: 
a.) MALE=1,FEMALE=2 
b.) DELIVERY TYPE: 
34. APGAR SCORE: 
35. OUTCOME: (LIST) 
36. MORBIDITY: (LIST) 
37. NICO:YES=1, NO=2 
38. DAYS: 
39. REASON:.......................................................................................................... 
40. SPECIAL INVESTIGATIONS: 
UREAM: ............................................. LDH: .............................................. 
KREAT:   ............................................. WCC: .............................................. 
AST:       .............................................. HB: .............................................. 
ALT: .................................................. HKT: .............................................. 
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GENERAL INFORMATION 
ADDRESS: 
 
 
 
 BORN AND RAISED: 
41. YOURSELF: ................................................................................................... 
42. YOUR MOTHER:….......................................................................................... 
43. YOUR FATHER:…………................................................................................ 
44. CURRENT PARTNER: (FATHER OF YOUR CHILD)...................................... 
45. YOUR PARTNER MOTHER:........................................................................... 
46. HAS SHE HAD TROMBOTIC EPISODES:...................................................... 
47. ANY COMPLICATIONS DURING YOUR PARTNER‟S BIRTH: 
......................................................................................................................... 
48. PREVIOUS PARTNER(S):     -CHILDHOOD AND PLACE OF BIRTH: 
......................................................................................................................... 
49. DO YOU HAVE SISTERS OR HALF SISTERS WHO HAVE THE 
FOLLOWING COMPLICATION PRETERM BIRTH=1, DEAD BABY=2, 
BLEEDING LATE IN PREGNANCY=3, HIGH BLOOD PRESSURE=4 
 
ADDRESS OF SISTER: 
 
 
 
 
50. DID YOUR MOTHER HAVE ANY OF THE FOLLOWING: 
PRETERM BIRTH=1, DEAD BABY=2, BLEEDING LATE IN PREGNANCY=3, 
HIGH BLOOD PRESSURE=4, TROMBOSIS=5  
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Appendix E: Fetal Growth Chart 
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Appendix F: Multiphor SSCP/HD gels and DNA Sequencing 
Electropherograms 
 
Figures 1 – 11 represents the results of Multiphor SSCP/HD analysis of each PCR 
fragment in the format of a figure that indicates the various conformations detected 
on the Multiphor gels and the subsequent genotypes for the identified variants as 
detected by bi-directional DNA sequencing.  Sequencing electropherograms 
representing the heterozygous status of each variant are included below the 
Multiphor gels.    
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b)     
i)  ii)   
  iii)  
 
Figure 1.  a)  Conformational variants as detected with Multiphor SSCP/HD analysis 
in PCR fragment 1a (variant allele indicated in bold).  b) Electropherograms 
representing the heterozygous status (arrow indicating point of variation) for the 
SNPs (i) c.-442 C>G, (ii) c.-191 G>C and (iii) c.-135 C>G.   
Conformations 1 2 3 
 
 
 
 
   
c.-442 C>G  
c.-191 G>C 
c.-189_-188insGCCGG 
c.-135 C>G 
CC 
GG 
WT 
CC 
CC 
GC 
HET 
CC 
CG 
GG 
WT 
CG 
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Figure 2.   a)  Electropherogram representing the homozygous wild type status for the PCR fragment 1a.   
     b)  Electropherogram representing the heterozygous status (arrow indicating point of variation) for insertion 
            c.-189_-188insGCCGG.   
GCCGG 
a) 
b) 
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a) 
 
 
 
 
 
 
 
 
 
 
 
b)       
i) ii) iii)  
Figure 3.  a)  Conformational variants as detected with Multiphor SSCP/HD analysis in PCR fragment 1b (variant allele indicated in 
bold).  b)  Electropherograms representing the heterozygous status (arrow indicating point of variation) for the SNPs (i) c.-92 A>T, 
(ii) c.-31 T>C and (iii) c.-12+75 C>A.   
Conformations 1 2 3 4 5 6 7 8 
 
 
 
 
        
c.-92 A>T 
c.-31 T>C  
c.-12+75 C>A 
AT 
CC 
CC 
AA 
TT 
CC 
AA 
CC 
CA 
 
AA 
CC 
CA 
 
AA 
TT 
CC 
AT 
CC 
CC 
AA 
CC 
AA 
AA 
TC 
CC 
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a)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
i)    ii)    
 
iii)  
 
 
Figure 4.  a) Conformational variants as detected with Multiphor SSCP/HD analysis 
in the amplicon containing exon 2 (variant allele indicated in bold). b) 
Electropherograms representing the heterozygous status (arrow indicating point of 
variation) for the SNPs (a) c.-11-43 G>A, (b) c.-11-13 A>T and (c) c.48+67 C>T.  
Conformations 1 2 3 4 
 
 
 
 
    
c.-11-43 G>A  
c.-11-13 A>T 
c.48+67 C>T 
AA 
TT 
CC 
GA 
AT 
CC 
GG 
AA 
CC 
GA 
AT 
CT 
125 
 
a)     b) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  a)  Conformational variants as detected with Multiphor SSCP/HD analysis 
in the fragment containing exon 4 (variant allele indicated in bold).   
b)  Electropherogram representing the heterozygous status (arrow indicating point of 
variation) for the SNP c.222 C>T; p.Ala74Ala.   
 
 
 
 
 
 
 
 
 
 
 
 
Conformations 1 2 
 
 
 
 
  
c.222 C>T;  
 p. Ala74Ala 
CC CT 
126 
 
a) 
 
 
 
 
 
 
 
 
 
 
b)     
i)  ii)   iii)  
Figure 6. a) Conformational variants as detected with Multiphor SSCP/HD analysis in the amplicon containning exon 5 (variant 
allele indicated in bold).  b) Electropherograms representing the heterozygous status (arrow indicating point of variation) for the 
SNPs (a) c.244-76 C>G,   (b) c.244-42 G>C and (c) c.292 G>T; p.Val98Leu.
Conformations 1 2 3 4 5 6 
 
 
 
 
      
c.244-76 C>G  
c.244-42 G>C  
c.292 G>T;  p.Val98Leu 
CC 
GG 
GG 
CG 
GG 
GG 
CG 
GC 
GG 
CC 
GC 
GG 
CC 
GG 
GT 
GG 
GG 
GG 
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      a) 
 
 
 
 
 
 
 
 
 
 
 
 
      b)   
   
 
Figure 7.  a)  Conformational variants as detected with Multiphor SSCP/HD analysis 
in the amplicon containing exon 7(variant allele indicated in bold).   
b)  Electropherograms representing the heterozygous status (arrow indicating) for 
the SNPs (i) c.449-17 G>A and (ii) c.528+38 C>T.   
 
 
Conformations 1 2 3 4 5 
 
 
 
 
     
c.449-17 G>A GG GA GG AA GA 
c.528+38 C>T CC CC CT CC CT 
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a)        
       
 
 
 
 
 
 
 
 
 
b) 
i)  ii)  iii)  
Figure 8.  a)  Conformational variants as detected with Multiphor SSCP/HD analysis in the amplicon containing exon 9 (variant 
allele indicated in bold).  b) Electropherograms representing the heterozygous status (arrow indicating) for the SNPs (i) c.589-5 
C>T, (ii) c.682+49 C>T and (iii) c.600 C>T; p.Asp110Asp. 
Conformations 1 2 3 4 
 
    
c.589-5 C>T CC CT CC CC 
c.682+49 C>T CC CC CT CC 
c.600 C>T; p.Asp110Asp CC CC CC CT 
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a) 
    
 
Figure 9. Electropherogram representing the heterozygous status (arrow 
indicating point of variation) for the SNP c.683-56 G>A.   
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
Figure 10. a)  Conformational variants as detected with Multiphor SSCP/HD 
analysis in the amplicon containing exon 12 (variant allele indicated in bold).  
b)  Electropherogram representing the heterozygous status (arrow indicating 
point of variation) for the SNP c.934 G>A; p.Gly312Ser. 
 
 
 
 
 
Conformations 1 2 
 
 
 
 
  
c.934 G>A; 
p.Gly312Ser 
GG GA 
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 b) 
i)  ii)  
iii) iv)            
Figure 11.  a)  Conformational variants as detected with Multiphor SSCP/HD 
analysis in the amplicon containing exon 13 (variant allele indicated in bold).  
b) Electropherograms representing the heterozygous status (arrow indicating 
point of variation) for the SNPs (i) c.961-30 A>G, (ii) c.961-24 C>G, (iii) c.975 
C>T; p.Gly325Gly and (d) c.*1057 A>G.  
Conformations 1 2 3 4 5 
  
    
 c.961-30 A>G AA AG AA AA AA 
c.961-24 C>G CC CC CC CC CG 
c.975 C>T; 
p.Gly325Gly 
CC CC CC CT CC 
c.*1057 A>G AA AA AG AA AA 
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Appendix G: Genotype and Allele Frequencies 
 
Genotype and allele frequencies as identified in the ANXA2 gene in the pre-
eclamptic maternal, fetal and control study cohorts are presented in Tables 1-12.  
The probability values (P-value) that would indicate significant association 
between maternal and control and fetal and control cohorts as verified in 
Microsoft® Office Excell (2003) by way of 2X3 contingency tables are indicated 
for all variants identified in the ANXA2 gene.  In the case of a dash, no result 
could be obtained.  Significant P-values (P<0.05) identified are highlighted in 
blue.  The variants that showed deviation from the Hardy-Weinberg equilibrium 
(P>0.05) are highlighted in red.   
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Table 1.  Genotype and allele frequencies of the c.-442 C>G and c.-191 G>C variants identified in the ANXA2 5‟UTR. 
 
c.-442 C>G 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 108 66 42 80 47 33 53 
CC 106 (0.981) 66 (1.000) 40 (0.952) 77 (0.963) 44 (0.936) 33 (1.000) 53 (1.000) 
CG 2 (0.019) 0 2 (0.048) 3 (0.037) 3 (0.064) 0 0 
GG 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
C 0.991 1.000 0.976 0.981 0.968 1.000 1.000 
G 0.009 0 0.024 0.019 0.032 0 0 
P value 0.320 - 0.110 0.156 0.064 - - 
HWE P value 0.9226 - 0.8744 0.8643 0.8212 - - 
c.-191 G>C 
  
  Total Patients  
  Maternal Fetal Controls 
  Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 108 66 42 80 47 33 53 
GG 103 (0.954) 64 (0.970) 39 (0.930) 79 (0.988) 47 (1.000) 32 (0.970) 52 (0.981) 
GC 5 (0.046) 2 (0.030) 3 (0.070) 0 (0.012) 0 1 (0.030) 1 (0.019) 
CC 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
G 0.977 0.985 0.964 1.000 1.000 0.985 0.991 
C 0.023 0.015 0.036 0 0 0.015 0.009 
P value 0.392 0.694 0.210 0.211 0.345 0.734 - 
HWE P value 0.8055 0.9005 0.8103 - - 0.9296 0.9447 
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Table 2.  Genotype and allele frequencies of the c.-189_-188GCCGG and c.-135 C>G variants identified in the ANXA2 
5‟UTR 
c.-189_-
188GCCGG 
  
  Total Patients  
  Maternal Fetal Controls 
  Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 108 66 42 80 47 33 53 
1_1 103 (0.954) 64 (0.970) 39 (0.930) 79 (0.988) 47 (1.000) 32 (0.970) 52 (0.981) 
1_Ins 5 (0.046) 2 (0.030) 3 (0.070) 1 (0.012) 0 1 (0.030) 1 (0.019) 
Ins_Ins 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
1 0.977 0.985 0.964 0.994 1.000 0.985 0.991 
Ins 0.023 0.015 0.036 0.006 0 0.015 0.009 
P value 0.392 0.694 0.210 0.769 0.345 0.734 - 
HWE P value 0.8055 0.9005 0.8103 0.9551 - 0.9296 0.9447 
c.-135 C>G 
  
  Total Patients  
  Maternal     Fetal     Controls 
  Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 108 66 42 80 47 33 53 
CC 106 (0.981) 65 (0.985) 40 (0.952) 77 (0.963) 44 (0.936) 33 (1.000) 52 (0.981) 
CG 2 (0.019) 1 (0.015) 2 (0.048) 3 (0.037) 3 (0.064) 0 1 (0.019) 
GG 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
C 0.991 0.992 0.976 0.981 0.968 1.000 0.991 
G 0.009 0.008 0.024 0.019 0.032 0 0.009 
P value 0.988 0.876 0.430 0.541 0.257 0.429 - 
HWE P value 0.9226 0.9506 0.8744 0.8643 0.8212 - 0.9447 
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Table 3.  Genotype and allele frequencies of the c.-92 G>C and c.-31 T>C variants identified in the ANXA2 5‟UTR.  
c.-92 A>T 
  
  Total Patients  
  Maternal Fetal Controls 
  Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 107 66 41 73 41 32 51 
AA 72 (0.673) 45 (0.682) 27 (0.659) 51 (0.699) 32 (0.780) 19 (0.594) 43 (0.843) 
AT 35 (0.327) 21 (0.318) 14 (0.341) 22 (0.301) 9 (0.220) 13 (0.406) 8 (0.157) 
TT 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
A 0.836 0.841 0.829 0.849 0.890 0.797 0.922 
T 0.164 0.159 0.171 0.151 0.110 0.203 0.078 
P value 0.039 0.063 0.055 0.086 0.466 0.019 - 
HWE P value 0.0431 0.1243 0.1874 0.1296 0.4299 0.1493 0.5433 
c.-31 T>C 
  
  Total Patients  
  Maternal Fetal Controls 
  Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 107 66 41 73 41 32 51 
TT 28 (0.261) 17 (0.258) 11 (0.268) 37 (0.507) 23 (0.561) 14 (0.438) 21 (0.412) 
TC 25 (0.234) 17 (0.258) 8 (0.195) 5 (0.068) 4 (0.098) 1 (0.031) 15 (0.294) 
CC 54 (0.505) 32 (0.485) 22 (0.537) 31 (0.425) 14 (0.341) 17 (0.531) 15 (0.294) 
P value 0.039 0.088 0.062 0.003 0.065 0.007 - 
Allelic 
Distribution 
T 0.379 0.386 0.366 0.541 0.610 0.453 0.559 
C 0.621 0.614 0.634 0.459 0.390 0.547 0.441 
P value 0.003 0.009 0.009 0.783 0.486 0.185 - 
HWE P value 0.0000 0.0002 0.0002 0.0000 0.0000 0.0000 0.0040 
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Table 4.  Genotype and allele frequencies of the c.-12+75 C>A and c.-11-43 G>A variants identified in the ANXA2 non-
coding regions.  
c.-12+75 
C>A 
  
  Total Patients  
  Maternal Fetal Controls 
  Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 107 66 41 73 41 32 51 
CC 88 (0.822) 55 (0.833) 33 (0.805) 64 (0.877) 36 (0.878) 28 (0.875) 44 (0.863) 
CA 16 (0.150) 10 (0.152)   6 (0.146) 9 (0.123)  5 (0.122)  4 (0.125) 6 (0.117) 
AA 3 (0.028) 2 (0.049)   2 (0.049) 0 0 0 1 (0.020) 
P value 0.812 0.821 0.661 0.485 0.666 0.726 - 
Allelic 
Distribution 
C 0.897 0.896 0.878 0.938 0.939 0.938 0.922 
A 0.103 0.104 0.122 0.062 0.061 0.063 0.078 
P value 0.490 0.495 0.323 0.607 0.646 0.700 - 
HWE P value 0.0501 0.0976 0.0426 0.5746 0.6776 0.7061 0.1837 
c.-11-43 
G>A 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 118 71 47 94 52 38 54 
GG 12 (0.102) 6 (0.085) 6 (0.128) 18 (0.191) 12 (0.231) 6 (0.158) 7 (0.130) 
GA 63 (0.534) 40 (0.563) 23 (0.489) 42 (0.447) 23 (0.442) 19 (0.500) 22 (0.407) 
AA 43 (0.364) 25 (0.352) 18 (0.383) 34 (0.362) 17 (0.327) 13 (0.342) 25 (0.463) 
P value 0.306 0.218 0.685 0.410 0.244 0.511 - 
Allelic 
Distribution 
G 0.369 0.366 0.372 0.415 0.452 0.408 0.333 
A 0.631 0.634 0.628 0.585 0.548 0.592 0.667 
P value 0.526 0.590 0.562 0.165 0.077 0.301 - 
HWE P value 0.1104 0.0718 0.7474 0.4396 0.8286 0.4398 0.5403 
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Table 5.  Genotype and allele frequencies for the c.-11-13 A>T and c.48+67 C>T variants identified in the ANXA2 non-
coding regions.  
c.-11-13 
A>T 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 118 71 47 94 52 38 54 
AA 12 (0.102) 6 (0.085) 6 (0.128) 18 (0.191) 12 (0.231) 6 (0.158) 7 (0.130) 
AT 63 (0.534) 40 (0.563) 23 (0.489) 42 (0.447) 23 (0.442) 
19 
(0.500) 22 (0.407) 
TT 43 (0.364) 25 (0.352) 18 (0.383) 34 (0.362) 17 (0.327) 
13 
(0.342) 25 (0.463) 
P value 0.306 0.218 0.685 0.410 0.244 0.511 - 
Allelic 
Distribution 
A 0.369 0.366 0.372 0.415 0.452 0.408 0.333 
T 0.631 0.634 0.628 0.585 0.548 0.592 0.667 
P value 0.526 0.590 0.562 0.165 0.077 0.301 - 
HWE P value 0.1104 0.0718 0.7474 0.4396 0.8286 0.4398 0.5403 
c.48+67 
C>T 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 118 71 47 94 56 38 54 
CC 117 (0.991) 70 (0.986) 47 (1.000) 94 (1.000) 56 (1.000) 38 (1.000) 54 (1.000) 
CT 1 (0.009) 1 (0.014) 0 0 0 0 0 
TT 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
C 0.996 0.993 1.000 1.000 1.000 1.000 1.000 
T 0.004 0.007 0 0 0 0 0 
P value 0.498 0.382 - - - - - 
HWE P value 0.9631 0.9523 - - - - - 
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Table 6.  Genotype and allele frequencies of the c.244-76 C>G and c.244-42 G>C variants identified in the ANXA2 non-
coding regions.  
c.244-76 
C>G 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 119 71 48 77 43 34 52 
CC 103 (0.865) 66 (0.930) 37 (0.771) 69 (0.896) 41 (0.953) 28 (0.824) 49 (0.942) 
CG 16 (0.135) 5 (0.070) 11 (0.229) 7 (0.091) 1 (0.023) 6 (0.176) 3 (0.058) 
GG 0 0 0 1 (0.013) 1 (0.023) 0 0 
P value - - - 0.154 0.392 - - 
Allelic 
Distribution 
C 0.933 0.965 0.885 0.942 0.965 0.912 0.971 
G 0.067 0.035 0.115 0.058 0.035 0.088 0.029 
P value 0.154 0.781 0.018 0.268 0.813 0.087 - 
HWE P value 0.4317 0.7584 0.3699 0.1269 0.0000 0.5726 0.8340 
c.244-42 
G>C 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 119 71 48 77 43 34 52 
GG 115 (0.966) 69 (0.942) 46 (0.958) 73 (0.948) 42 (0.947) 31 (0.912) 51 (0.981) 
GC 4 (0.034) 2 (0.028) 2 (0.042) 4 (0.052) 1 (0.023) 3 (0.088) 1 (0.019) 
CC 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
G 0.983 0.986 0.979 0.974 0.988 0.956 0.990 
C 0.017 0.014 0.021 0.026 0.012 0.044 0.010 
P value 0.610 0.752 0.514 0.350 0.892 0.142 - 
HWE P value 0.8521 0.9042 0.8828 0.8150 0.9385 0.7878 0.9442 
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Table 7.  Genotype and allele frequencies of the c.499-17 G>A and c.528+38 C>T variants identified in the ANXA2 non-
coding regions.  
c.449-17 
G>A 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 117 71 46 87 50 37 53 
GG 87 (0.744) 47 (0.662) 40 (0.870) 62 (0.713) 30 (0.600) 32 (0.865) 34 (0.642) 
GA 28 (0.239) 23 (0.324) 5 (0.109) 20 (0.230) 15 (0.300) 5 (0.135) 19 (0.358) 
AA 2 (0.017) 1 (0.014) 1 (0.021) 5 (0.057) 5 (0.100) 0 0 
P value 0.191 0.646 0.010 0.073 0.060 - - 
Allelic 
Distribution 
G 0.863 0.824 0.924 0.828 0.750 0.932 0.821 
A 0.137 0.176 0.076 0.172 0.250 0.068 0.179 
P value 0.3309 0.948 0.032 0.884 0.216 0.030 - 
HWE P value 0.8829 0.3259 0.1238 0.0697 0.1573 0.6594 0.1119 
c.528+38 
C>T 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 117 71 46 87 50 37 53 
CC 109 (0.932) 66 (0.930) 43 (0.935) 85 (0.977) 48 (0.960) 37 (1.000) 52 (0.981) 
CT 8 (0.068) 5 (0.040) 3 (0.065) 2 (0.023) 2 (0.040) 0 1 (0.019) 
TT 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
C 0.966 0.965 0.967 0.989 0.980 1.000 0.991 
T 0.034 0.035 0.033 0.011 0.020 0 0.009 
P value 0.188 0.191 0.248 0.870 0.527 0.402 - 
HWE P value 0.7018 0.7584 0.8192 0.9136 0.8853 - 0.9447 
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Table 8.  Genotype and allele frequencies of the c.589-5 C>T and c.682+49 C>T variants identified in the ANXA2 non-
coding regions.  
c.589-5 
C>T 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 120 72 48 89 51 38 52 
CC 115 (0.958) 69 (0.958) 46 (0.958) 82 (0.921) 47 (0.922) 35 (0.921) 52 (1.000) 
CT 5 (0.042) 3 (0.042) 2 (0.042) 7 (0.079) 4 (0.078) 3 (0.079) 0 
CC 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
C 0.979 0.979 0.979 0.961 0.961 0.961 1.000 
T 0.021 0.021 0.021 0.039 0.039 0.039 0 
P value 0.138 0.139 0.139 0.041 0.041 0.041 - 
HWE P value 0.8157 0.8567 0.8828 0.6994 0.7707 0.8000 - 
c.682+49 
C>T 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 120 72 48 89 51 38 52 
CC 115 (0.958) 69 (0.958) 46 (0.958) 85 (0.955) 50 (0.980) 35 (0.921) 48 (0.923) 
CT 5 (0.0417) 3 (0.042) 2 (0.042) 4 (0.045) 1 (0.020) 3 (0.079) 4 (0.077) 
TT 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
C 0.979 0.979 0.979 0.978 0.990 0.961 0.962 
T 0.021 0.021 0.021 0.022 0.010 0.039 0.038 
P value 0.347 0.408 0.465 0.435 0.181 0.972 - 
HWE P value 0.8157 0.8567 0.8828 0.8283 0.9436 0.8000 0.7730 
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Table 9.  Genotype and allele frequencies of the c.683-56 G>A and c.961-30 A>G variants identified in the ANXA2 non-
coding regions.  
c.683-56 
G>A 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 120 72 48 86 50 36 53 
GG 67 (0.558) 37 (0.514) 30 (0.625) 53 (0.616) 29 (0.580) 24 (0.667) 27 (0.509) 
GA 49 (0.408) 32 (0.444) 17 (0.354) 29 (0.337) 18 (0.360) 11 (0.305) 24 (0.453) 
AA  4 (0.034)  3 (0.042)  1 (0.021)  4 (0.047)   3 (0.060)   1 (0.028)   2 (0.038) 
P value 0.837 0.991 0.486 0.395 0.594 0.338 - 
Allelic 
Distribution 
G 0.763 0.736 0.802 0.785 0.760 0.819 0.736 
A 0.238 0.264 0.198 0.215 0.240 0.181 0.264 
P value 0.596 0.996 0.266 0.348 0.690 0.194 - 
HWE P value 0.1628 0.2218 0.4235 0.9896 0.9259 0.8449 0.2301 
c.961-30 
A>G 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 118 71 47 90 52 38 53 
AA 117 (0.992) 71 (1.000) 46 (0.979) 90 (1.000) 52 (1.000) 36 (0.947) 51 (0.962) 
AG    1 (0.008) 0   1 (0.021) 0 0   2 (0.053)   2 (0.038) 
GG 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
A 0.996 1.000 0.989 1.000 1.000 0.974 0.981 
G 0.004 0 0.011 0 0 0.026 0.019 
P value 0.180 0.100 0.633 0.064 0.159 0.735 - 
HWE P value 0.9631 - 0.9412 - - 0.8677 0.8887 
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Table 10.  Genotype and allele frequencies of the c.222 C>T; p.Ala74Ala and c.292 G>T; p.Val98Leu variants identified in 
the ANXA2 coding regions.  
c.222 C>T; 
p.Ala74Ala 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 123 78 45 96 58 38 53 
CC 123 (1.000) 78 (1.000) 45 (1.000) 96 (1.000) 58 (1.000) 38 (1.000) 50 (0.943) 
CT 0 0 0 0 0 0  3 (0.057) 
TT 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
C 1.000 1.000 1.000 1.000 1.000 1.000 0.972 
T 0 0 0 0 0 0 0.028 
P value 0.008 0.035 0.108 0.019 0.068 0.139 - 
HWE P value - - - - - - 0.8321 
c.292 G>T; 
p.Val98Leu 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 119 71 48 77 43 34 52 
GG 114 (0.958) 66 (0.930) 48 (1.000) 75 (0.974) 41 (0.953) 34 (1.000) 50 (0.963) 
GT    5 (0.042)  5 (0.070) 0 2 (0.026)  2 (0.047) 0  2 (0.037) 
TT 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
G 0.979 0.965 1.000 0.987 0.977 1.000 0.981 
T 0.021 0.035 0 0.013 0.023 0 0.019 
P value 0.915 0.456 0.172 0.690 0.847 0.250 - 
HWE P value 0.8149 0.7584 - 0.9081 0.8759 - 0.8876 
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Table 11.  Genotype and allele frequencies for the c.600 C>T; p.Asp110Asp and c.934 G>A; p.Gly312Ser variants 
identified in ANXA2 coding regions.  
 
c.600 C>T; 
p.Asp110Asp 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 120 72 48 89 51 38 52 
CC 120 (1.000) 72 (1.000) 48 (1.000) 89 (1.000) 51 (1.000) 38 (1.000) 51 (0.981) 
CT 0 0 0 0 0 0  1 (0.019) 
TT 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
C 1.000 1.000 1.000 1.000 1.000 1.000 0.990 
T 0 0 0 0 0 0 0.010 
P value 0.128 0.238 0.335 0.190 0.321 0.391 - 
HWE P value - - - - - - 0.9442 
c.934 G>A; 
p.Gly312Ser 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 119 70 49 89 51 38 52 
GG 116 (0.975) 69 (0.986) 47 (0.959) 86 (0.966) 50 (0.980) 36 (0.947) 48 (0.923) 
GA    3 (0.025)  1 (0.014)   2 (0.041)  3 (0.034)   1 (0.020)   2 (0.053)   4 (0.077) 
AA 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
G 0.987 0.993 0.980 0.983 0.990 0.974 0.962 
A 0.013 0.007 0.020 0.017 0.010 0.026 0.038 
P value 0.120 0.088 0.450 0.260 0.181 0.654 - 
HWE P value 0.8892 0.9520 0.8841 0.8715 0.9436 0.8677 0.7730 
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Table 12.  Genotype and allele frequencies for the variant c.975 C>T; p.Gly325Gly identified in ANXA2 coding region and 
the variant c.*1057 A>G identified in the ANXA2 3‟UTR.  
c.975 C>T; 
p.Gly325Gly 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 118 71 47 90 52 38 53 
CC 116 (0.983) 69 (0.972) 47 (1.000) 89 (0.989) 51 (0.981) 38 (1.000) 51 (0.962) 
CT    2 (0.017)  2 (0.028) 0  1 (0.011)  1 (0.019) 0  2 (0.038) 
TT 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
C 0.992 0.986 1.000 0.994 0.990 1.000 0.981 
T 0.008 0.014 0 0.006 0.010 0 0.019 
P value 0.408 0.767 0.181 0.286 0.572 0.229 - 
HWE P value 0.9260 0.9042 - 0.9577 0.9442 - 0.8887 
c.*1057 
A>G 
    
Total Patients  
Maternal Fetal Controls 
Total 
Mixed 
Ancestry Black Total 
Mixed 
Ancestry Black Total 
Genotype 
Distribution 
n 118 71 47 90 53 37 53 
AA 117 (0.991) 71 (1.000) 46 (0.979) 90 (1.000) 53 (1.000) 37 (1.000) 53 (1.000) 
AG    1 (0.009) 0   1 (0.021) 0 0 0 0 
GG 0 0 0 0 0 0 0 
P value - - - - - - - 
Allelic 
Distribution 
A 0.996 1.000 0.989 1.000 1.000 1.000 1.000 
G 0.004 0 0.011 0 0 0 0 
P value 0.502 - 0.287 - - - - 
HWE P value 0.9631 - 0.9412 - - - - 
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Appendix H: Comparison of the Genotype and Allele 
Frequencies in Different Ethnic Populations 
 
Genotype and allele frequencies of previously documented variants identified in 
the ANXA2 gene in this study were compared to the genotype and allele 
frequencies identified in European, Asia and Sub-Saharan African populations in 
Table 1.  Information on the markers identified and included in the haplotype 
analysis is presented in Table 2.   
 
 
 
Table 1. Genotype and allele frequencies of previously documented SNPs 
(http://www.ncbi.nlm.nih.gov/SNP/) identified in this study. 
 
   Populations This study 
Region 
Variant 
(dbSNP) 
Genotypes 
& 
Alleles 
European Asian 
Sub-
Saharan 
African 
Maternal  
PE 
Patients 
Controls 
5’UTR 
 
rs12904657  
 
(c.-31 T>C) 
 
TT 
TC 
CC 
T 
C 
 
 
Not 
Available 
 
 
 
Not 
Available 
 
 
 
Not 
Available 
 
 
0.261 
0.234 
0.505 
0.379 
0.621 
 
(n=107) 
 
0.412 
0.294 
0.294 
0.559 
0.441 
 
(n=51) 
 
Coding 
rs1059688 
 
(c.929 G>T; 
p.Val98Leu) 
 
GG 
GT 
TT 
G 
T 
Not 
Available 
Not 
Available 
Not 
Available 
 
0.958 
0.042 
0.000 
0.979 
0.021 
 
(n=119) 
 
0.963 
0.037 
0.000 
0.981 
0.019 
 
(n=52) 
 
rs1244554 
 
(c.975 C>T; 
p.Gly325Gly) 
 
 
 
CC 
CT 
TT 
C 
T 
 
0.233 
0.400 
0.367 
0.433 
0.567 
 
(n=120) 
 
0.267 
0.467 
0.267 
0.500 
0.500 
 
(n=90) 
 
0.317 
0.483 
0.200 
0.558 
0.442 
 
(n=120) 
 
0.983 
0.017 
0.000 
0.992 
0.008 
 
(n=118) 
 
0.962 
0.037 
0.000 
0.981 
0.019 
 
(n=53) 
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   Populations This study 
 
Region 
Variant 
(dbSNP) 
Genotypes 
& 
Alleles 
European Asian 
Sub-
Saharan 
African 
Maternal 
PE 
Patients 
Controls 
Non-
Coding 
rs12904756 
 
(c.-12+75 
C>A) 
 
CC 
CA 
AA 
C 
A 
 
 
Not 
Available 
 
 
Not 
Available 
 
 
Not  
Available 
 
0.822 
0.150 
0.028 
0.897 
0.103 
 
(n=107) 
 
0.863 
0.117 
0.020 
0.922 
0.078 
 
(n=51) 
rs11858864 
 
(c.-11-43 
G>A) 
 
GG 
GA 
AA 
G 
A 
 
 
0.094 
0.151 
0.755 
0.170 
0.830 
 
(n=106) 
 
0.000 
0.000 
1.000 
0.000 
1.000 
 
(n=88) 
 
0.113 
0.302 
0.585 
0.264 
0.736 
 
(n=106) 
 
0.102 
0.534 
0.364 
0.369 
0.631 
 
(n=118) 
 
0.130 
0.407 
0.463 
0.333 
0.667 
 
(n=54) 
rs11855679 
 
(c.-11-13 
A>T) 
 
AA 
AT 
TT 
A 
T 
 
 
0.857 
0.143 
0.000 
0.929 
0.071 
 
(n=98) 
 
1.000 
0.000 
0.000 
1.000 
0.000 
 
(n=90) 
 
0.600 
0.291 
0.109 
0.745 
0.255 
 
(n=110) 
 
0.102 
0.534 
0.364 
0.369 
0.631 
 
(n=118) 
 
0.130 
0.407 
0.463 
0.333 
0.667 
 
(n=54) 
rs3743268 
 
(c.48+67 
C>T) 
 
CC 
CT 
TT 
C 
T 
 
 
0.600 
0.350 
0.050 
0.775 
0.225 
 
(n=120) 
 
0.356 
0.422 
0.222 
0.567 
0.433 
 
(n=90) 
 
0.948 
0.052 
0.000 
0.974 
0.026 
 
(n=116) 
 
0.991 
0.009 
0.000 
0.996 
0.004 
 
(n=118) 
 
1.000 
0.000 
0.000 
1.000 
0.000 
 
(n=54) 
rs12898604 
 
(c.449-17 
G>A) 
 
GG 
GA 
AA 
G 
A 
 
 
0.583 
0.300 
0.117 
0.733 
0.267 
 
(n=120) 
 
0.289 
0.422 
0.289 
0.500 
0.500 
 
(n=90) 
 
0.767 
0.233 
0.000 
0.883 
0.117 
 
(n=120) 
 
0.744 
0.239 
0.017 
0.863 
0.137 
 
(n=117) 
 
0.642 
0.358 
0.000 
0.821 
0.179 
 
(n=53) 
rs11633619 
 
(c.683-56 
G>A) 
 
 
GG 
GA 
AA 
G 
A 
 
 
0.383 
0.400 
0.217 
0.583 
0.417 
 
(n=120) 
 
0.689 
0.267 
0.044 
0.822 
0.178 
 
(n=90) 
 
0.717 
0.250 
0.033 
0.842 
0.158 
 
(n=120) 
 
0.558 
0.408 
0.034 
0.763 
0.238 
 
(n=120) 
 
0.509 
0.453 
0.038 
0.736 
0.264 
 
(n=53) 
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Table 2.  Markers in accordance with variants in the ANXA2 gene as imported 
into Haploview.  
Marker Variant 
1 c.-442 C>G 
2 c.-191 G>C 
3 c.-189_-188insGCCGG 
4 c.-135 C>G 
5 c.-92 A>T 
6 c.-31 T>C 
7 c.-12+75 C>A 
8 c.-11-43 G>A 
9 c.-11-13 A>T 
10 c.48+67 C>T 
11 c.222 C>T; p.Ala74Ala 
12 c.244-76 C>G 
13 c.244-42 G>C 
14 c.292 G>T; p.Val98Leu 
15 c.449-17 G>A 
16 c.528+38 C>T 
17 c.589-5 C>T 
18 c.600 C>T; p.Asp110Asp 
19 c.682+49 C>T 
20 c.683-56 G>A 
21 c.934 G>A; p.Gly312Ser 
22 c.961-30 A>G 
23 c.961-24 C>G 
24 c.975 C>T; p.Gly325Gly 
25 c.*1057 A>G 
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Objectives: Reduced levels of PP13 early in pregnancy are associated with a higher 
incidence of pre-eclampsia in later gestation.  PP13 and Annexin II have been co-localised to 
the brush border membrane of syncytiotrophoblasts, and form a complex which is 
transported to the maternal circulation.  It is speculated that genetic alteration in the gene 
encoding Annexin II (ANXA2) could underlie the reduced PP13 levels. 
 
Methods: We report the screening of 6 of the 13 ANXA2 exons in a cohort comprising 77 
pre-eclampsia maternal-fetal pairs and 50 healthy control individuals.  The various 
conformations identified on Multiphor SSCP/HD gels were subjected to automated 
sequencing, and subsequently to REA, to confirm the genotypes in the remainder of the 
cohort.  
 
Results: Seven novel SNPs were identified, including intronic: IVS7+38 (C/T), IVS6-17 (A/G) 
[rs12898604], IVS8-5 (C/T), IVS9+49 (C/T), IVS12-30 (A/G), IVS12-24 (C/G) and exonic 
Ser96Gly (G/A), Thr97Ala (A/G) and Gly15 (C/T) [rs12442554] loci.  Significant association 
was demonstrated at two loci:  Ser96Gly was identified in 4% of the controls, but was absent 
in the maternal cohort (p=0.012), implying a protective effect or reduced pre-eclampsia risk.  
Marginal association (p=0.03) was demonstrated at intronic IVS8-5 C/T locus in the fetal 
cohort (4%), but was absent in the controls. 
 
Conclusion: This pilot study provides evidence for genetic alteration in the 
ANXA2 gene, which could impact on binding with PP13.  Intronic splicing and 
coding variant analyses and their potential effects on gene expression, protein 
functionality and interaction with PP13 should be included in follow-up studies. 
